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DUAL ROLE OF ANTIMICROBIAL PEPTIDE CATHELICIDIN IN  
ALCOHOL-ASSOCIATED LIVER DISEASE 
Fengyuan Li 
April 16, 2020 
Patients with alcohol-associated liver disease (ALD) have high morbidity and 
mortality in its severe forms. One of the major features in different forms of ALD is the 
altered gut microbiota. Antimicrobial peptides (AMPs) play a crucial role in maintaining 
gut microbiota homeostasis. LL-37 (known as CRAMP in mouse) is the sole member of 
the human cathelicidin family and has piqued great research interest for its dual role in 
modulating microbiota and the immune response in metabolic diseases. Inflammasome 
activation is an important component of the liver pathophysiology in ALD and requires 
two signals for its full activation to induce the maturation and release of IL-1β, to induce 
inflammation. Whether LL-37/CRAMP is involved in the regulation of inflammasome 
activation in ALD remains unclear. The first aim of this dissertation was to investigate 
whether CRAMP protects the liver from alcohol-induced injury and whether the effect is 
mediated through regulation of gut microbiota and inflammasome activation inhibition. 
Indeed, CRAMP deficiency exacerbated, while exogenous CRAMP peptide alleviated, 
alcohol-induced liver injury through inhibition of inflammasome activation by decreasing 
LPS function and uric acid (UA) production. 
vi 
 
Obese alcoholic subjects have elevated serum ALT levels and are often at high 
risk of progressing from simple fatty liver to advanced ALD. Increased neutrophil 
infiltration and chemokine expression were linked to the synergistic effects of alcohol 
consumption and obesity. LL-37 and CRAMP has been recognized as chemoattractants to 
neutrophils and inflammatory monocytes through membrane chemokine receptors. The 
second aim was to investigate the role of CRAMP in binge alcohol-induced liver injury in 
high fat diet (HFD)-fed mice. CRAMP knockout (Camp-/-) mice were protected from 
HFD feeding induced weight gain and adipocyte enlargement, liver injury and steatosis; 
importantly, Camp-/- mice had significantly fewer infiltrated neutrophils in the liver and 
decreased chemokine expression compared to WT mice. High fat diet plus ethanol 
(HFD+E) treatment significantly increased hepatic protein levels of CRAMP, which co-
localized with Ly6G-positive neutrophils.  
In summary, the dual effects of CRAMP in alcohol-associated liver disease have 
been explored. CRAMP plays a protective role in binge alcohol-induced liver injury in 
chronic alcohol-fed mice, through the inhibition of LPS function and UA-induced 
inflammasome activation. In contrast, CRAMP acts as a chemoattractant for neutrophil 
infiltration in HFD-fed mice challenged with binge alcohol, exacerbating liver injury. 
The present study suggested that the role of CRAMP in alcohol-associated liver disease is 
dependent on the disease status and targeting CRAMP may represent a novel therapeutic 
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CHAPTER 1 INTRODUCTION 
 
 
1.1 Overview of Alcohol-associated Liver Disease (ALD) 
The excessive and long-term consumption of alcohol causes serious health 
consequences to individuals and can also exert heavy burdens onto the society and 
economies worldwide. Accounting for 3.3 million deaths in 2012 1 and ranking as the 
fifth leading global cause of preventable morbidity 2,3, the harmful use of alcohol over 
decades damages nearly every organ in the body, including the brain 4, heart 5 , pancreas 6 
and liver 7. Excessive alcohol drinking is strongly associated with several types of cancer 
including breast cancer 8 and colorectal cancer 9, and studies have shown that high doses 
of alcohol consumption can directly suppress a wide range of immune responses, and that 
alcohol abuse is associated with an increased incidence of a number of infectious diseases 
10.  
The liver acts as the major organ for alcohol metabolism, and thus it sustains the 
earliest and greatest degree of tissue injury from excessive alcohol drinking 11,12. 
Alcohol-associated liver disease (ALD) is a term that encompasses the liver 
manifestations of alcohol overconsumption, including fatty liver, alcohol-associated 
hepatitis, and chronic hepatitis with liver fibrosis or cirrhosis, and sometimes progressing 
to liver cancer, or hepatocellular carcinoma (HCC) 13 (Figure 1.1). ALD has profound 
economic and health impact worldwide. According to the National Institute on Alcohol
2 
 
Abuse and Alcoholism (NIAAA) Surveillance Report 2016, liver cirrhosis ranked as the 
12th leading cause of death in the United States, and about half of all cirrhosis deaths in 
2013 were alcohol related 3. Steatosis is the earliest and most common response in most 
heavy drinkers, and is usually reversible 14. Alcohol-associated hepatitis is a more severe, 
inflammatory type of liver injury characterized by swollen, dying hepatocytes (i.e., 
ballooning degeneration), infiltrated neutrophils and inflammatory monocytes, and the 
development of tangled aggregates of insoluble proteins called Mallory-Denk bodies 
within hepatocytes. The activation of Kupffer cells (KCs), the resident macrophages in 
the liver, is critical in alcohol-associated hepatitis development 15. Fibrosis and its 
terminal or late stage, cirrhosis, refer to the deposition of abnormal amounts of 
extracellular matrix proteins, principally by activated hepatic stellate cells (HSCs). 
Patients initially exhibit active pericellular fibrosis, which may progress to cirrhosis, the 
late stage of hepatic scarring 16.  
 




Classic treatment of ALD includes abstinence, which is the most effective way to 
manage ALD for subjects at early disease stage 17. Nutritional support, corticosteroids, 
and liver transplantation are also used based on disease severity and other complications 
18-20. Despite major progress made in the past decades in understanding the pathogenesis 
of ALD and the improvement in ALD management, currently there is still no FDA (Food 
and Drug Administration) approved therapy for any stage of ALD. New targeted 
therapies for ALD are urgently needed.  
It is important to understand how ethanol damages the liver. Ethanol is mainly 
metabolized in hepatocytes, the main parenchymal cells of the liver, which make up to 
about 70 percent of the liver mass 21. Hepatocytes express the highest levels of two major 
enzymes involved in ethanol metabolism, alcohol dehydrogenase (ADH) in the cytosol 
and cytochrome P450 2E1 (CYP2E1), which resides in the smooth endoplasmic 
reticulum (ER). Ethanol is oxidized to acetaldehyde by ADH and then to acetate in the 
mitochondria by aldehyde dehydrogenase 2 (ALDH2). These sequential oxidation 
processes produce two mole equivalents of reduced nicotinamide adenine dinucleotide 
(NADH), which can alter the cellular redox potential and can enhance lipid synthesis. 
The oxidation of ethanol can also take place in the presence of molecular oxygen and 
hydrogen peroxide by CYP2E1 and another enzyme that is highly expressed in 
hepatocyte, catalase. These two pathways also generate acetaldehyde, contributing to 
further oxidation of acetaldehyde to acetate by ALDH2 in the mitochondria 22. 
Acetaldehyde is a highly toxic substance and a known carcinogen 22, while acetate is less 
active and can be broken down into water and carbon dioxide for easy elimination. 
Acetaldehyde can covalently bind to proteins, lipids and nucleic acids to form 
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acetaldehyde adducts, which can, in turn, disrupt the structure and function of these 
macromolecules 11,23. This is particularly evident in the liver, where the bulk of alcohol 
metabolism takes place. Some alcohol metabolism also occurs in other tissues, including 
the pancreas 24 and the brain, causing damage to cells and tissues. It has been shown that 
small amounts of alcohol are metabolized to acetaldehyde in the gastrointestinal tract, 
exposing these tissues to acetaldehyde’s damaging effects 25. Additionally, small amounts 
of alcohol are also removed by interacting with fatty acids to form compounds called 
fatty acid ethyl esters (FAEEs). These compounds have been shown to contribute to 
damage to the liver and pancreas 24. 
The oxidative pathway of alcohol metabolism generates the toxic metabolite, 
acetaldehyde, and it gives rise to large amounts of reactive oxygen species (ROS) , which 
are considered the key toxins in alcohol-mediated liver injury 26-30. In heavy drinkers, 
accelerated alcohol metabolism by higher levels of CYP2E1 puts liver cells in metabolic 
peril, because more CYP2E1 not only produces more acetaldehyde, but also generates 
greater amounts of various other ROS, including hydroxyethyl radicals (i.e., free-radical 
forms of ethanol), superoxide anions (O2−) and hydroxyl radicals (·OH). Continuous 
generation of these reactive molecules eventually creates the condition known as oxidant 
stress or oxidative stress. Under these conditions, the rate of ROS generation exceeds the 
liver’s capacity to neutralize them with natural antioxidants, such as glutathione and 
vitamins E, A, and C, or to remove them using antioxidant enzymes. Animal studies 
showed that chronic ethanol consumption leads to decreased activities and/or amounts of 
several antioxidant enzymes, which worsens the hepatocytes’ oxidant burden 31-33. 
5 
 
Oxidant stress is further exacerbated when the generated ROS undergo secondary 
reactions with proteins and unsaturated lipids 11.  
Impaired innate and adaptive immunity is another hallmark of ALD. Alcohol can 
impair both innate and adaptive immunity, either directly through ROS production or 
indirectly by increasing gut permeability and consequently increasing endotoxin and 
bacterial translocation that contribute to the development of ALD 34. On one hand, the 
metabolism of alcohol itself leads to the production of ROS, and the formation of 
immunogenic protein adducts (which induces an immune reaction with antibody 
production or T-cell activation, or both), causing DNA damage, mutagenesis and direct 
cell death, contributing to tissue damage. On the other hand, alcohol consumption causes 
leaky gut and reduction of antimicrobial peptides (AMPs), which allows the translocation 
of pathogen-associated molecular patterns (PAMPs) such as LPS into the portal 
circulation. The activation of KCs by LPS results in up-regulation of pro-inflammatory 
cytokines through the activation of nuclear factor kappa B (NF-κB), which promotes the 
development of ALD. Several components of the innate and adaptive immune responses 
are involved in the hepatic response to injury. Within the liver, PAMPs are presented to 
Toll-like receptors (TLRs) on macrophages and induces the expression of inflammatory 
cytokines and chemokines, causing liver injury, for example, interleukin (IL)-1β, tumor 
necrosis factor (TNF)-a, chemokine (C-X-C motif) ligand (CXCL)-1 and CXCL-2. 
CXCL-1 and CXCL-2 act as chemoattractants through the chemokine receptor C-X-C 
motif chemokine receptor (CXCR)-1 and CXCR-2 on neutrophil to recruit neutrophils, 
which induces more pro-inflammatory cytokine expression and further causing liver 
injury. T helper 17 (Th17) cells are activated and secret pro-inflammatory cytokine IL-17 
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which further increase neutrophil infiltration. In addition, TNF-α and fas cell surface 
death receptor (Fas) produced by T cells also leads to apoptotic hepatocyte cell death 
through the Fas death receptor and TNF receptor pathways 35.  
Obesity has long been recognized as one of the most common comorbidities of 
ALD, and it can strongly affect the initiation and progression of the disease. The 
interaction of excessive alcohol drinking and obesity has been confirmed in a large 
number of comprehensive clinical studies involving obese alcoholics, non-obese 
alcoholics and obese non-alcoholics as controls. Higher serum ALT levels were often 
found in obese alcoholics and this group of alcoholic subjects usually has a higher risk of 
progressing from fatty liver to advanced forms of ALD 36-43. Oxidative stress and 
nitrosative damage were linked to the synergistic effects of obesity and alcohol 
consumption in diet-induced obesity animal models. An increased pro-inflammatory 
response and impaired hepatic lipid metabolism were seen in genetically obese rodent 
models 44. A recent study showed that feeding mice with short- or long-term high fat diet 
(HFD) plus a single ethanol binge synergistically increased the serum and hepatic free 
fatty acids, chemokine CXCL1 expression and exaggerated neutrophil infiltration in the 
liver, eventually leading to severe liver injury 45.  
 
1.2 The Gut-Liver Axis 
Gut microbiota changes have been identified as one of the major features in 
different stages of ALD, emphasizing the importance of gut-liver axis relevant to ALD 
46,47 (Figure 1.2). Although alcohol is mainly metabolized in the liver, it is well-known 
that alcohol consumption causes gut lumen bacterial overgrowth and dysbiosis, intestinal 
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mucosal damage, and increased intestinal permeability, leading to increased translocation 
of bacteria and their products, such as endotoxin (mainly lipopolysaccharide, LPS) into 
the portal circulation and binds with LPS binding protein (LBP). Bacteria and their 
products stimulate the production of ROS and pro-inflammatory cytokines and 
chemokines, resulting in damage to liver cells and the development of liver injury 48,49. 
Gut bacteria-derived endotoxin acts through pattern recognition receptors such as toll-like 
receptors (TLRs) which are expressed in liver resident macrophages--KCs--as well as 
other cell types in the liver. The major endotoxin, LPS, is derived from the cell walls of 
gram-negative bacteria in the gut lumen, binds with LBP and recognizes TLR4 and its 
co-receptors, CD14 and MD2 in the liver when penetrating the intestinal barrier and 
entering into blood stream. Deficiency in the TLR4 complex, such as mutation of TLR4, 
lack of CD14 and/or MD2, protects mice from alcohol-induced liver injury. It has been 
widely demonstrated that alcohol consumption induces endotoxemia 50,51. These 
observations suggest that gut bacteria homeostasis, intestinal barrier integrity, and hepatic 
TLRs are important in the pathogenesis of ALD. 
 
Figure 1.2 The gut-liver axis. 
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Accumulating evidence demonstrated that intestinal dysbiosis is a risk factor in 
ALD development/progression. Intestinal dysbiosis is defined as an imbalance of the 
different microbial entities in the intestine with a disruption of symbiosis 52. Both chronic 
and acute alcohol consumption lead to bacterial overgrowth and dysbiosis in both the 
small and large intestine in experimental animals 29,52-54 and in human alcoholic subjects 
55-60.  
In a rat model of ALD using intragastric gavage feeding, Multu and colleagues 
showed that alcohol ingestion did not change microbiota composition in 4-6 weeks of 
feeding, but did significantly alter the mucosa-associated microbiota in the colon after 
10-weeks of feeding 50. A recent study by Yan et al. further demonstrated that 3-weeks of 
alcohol ingestion in mice led to bacterial overgrowth in the proximal small intestine, and 
dysbiosis, which was associated with the suppression of the anti-microbial peptides, 
Reg3β and Reg3γ. Moreover, the population of Lactobacilli was depleted in alcohol-fed 
mice 61. Germ-free mice had less fat in the liver after alcohol feeding compared to 
conventional mice; moreover, transplantation of intestinal contents from conventional 
mice to germ-free mice induced inflammation in both intestine and liver 54.  
In 1984, Bode and co-workers found that the bacterial population was increased 
in the jejunum of alcoholics compared with hospitalized control patients 62. These same 
investigators further showed a higher prevalence of small intestine bacterial overgrowth 
in chronic alcoholics compared to controls using a breath test 63. These observations were 
later confirmed by other groups 57,59. Recently, Bajaj et al. studied bacterial composition 
in the 244 alcoholic cirrhotic patients and 25 age-matched controls. Using an index, 
cirrhosis dysbiosis ratio (CDR, a low number indicating dysbiosis), the authors found that 
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intestinal dysbiosis was more severe in decompensated cirrhotics compared to 
compensated cirrhotics 64. Using the lactulose breath test, Gabbard and co-workers 
observed that moderate drinking was a strong risk factor for small intestine bacterial 
overgrowth 65.  
 
1.3 Hepatic Inflammation and Inflammasome Activation 
Inflammatory reactions play an important role in the pathogenesis of ALD. 
Inflammatory processes are primary contributors to the development and progression of 
alcohol associated steatohepatitis (ASH), with severe AH characterized by non-resolving 
inflammation 66. Hepatic inflammation in the development and progression of ASH is a 
complex response to gut dysbiosis, impaired intestinal barrier function, hepatocellular 
stress and death, as well as inter-organ crosstalk. In response to chronic, excessive 
alcohol exposure, hepatocytes themselves also contribute to the inflammatory process. 
The hepatocytes produce large number of chemokines and inflammatory mediators and 
release damage-associated molecular patterns during injury and death. These cellular 
responses are mediated and accompanied by changes in the expression of pro- and anti-
inflammatory cytokines and chemokines, as well as by signals which orchestrate the 
recruitment of immune cells and activation of the inflammatory process 67.  
The innate immune system represents the first-line response to invading microbes 
and tissue damage. Many of the proteins and cells involved in innate immunity are 
produced by, and reside in, the liver. This abundance in immune cells and proteins 
reflects the liver's adaptation to various immune challenges but also makes the organ 
particularly vulnerable to alcohol's effects 68. Heavy alcohol consumption exacerbates the 
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translocation of microbes and microbial products from the gut lumen to the liver via the 
portal vein. Alcohol and its toxic metabolites further damage the gut barrier. These 
immune challenges disrupt the liver's normally fine-tuned immune signaling pathways, 
leading to activation of various pathogen- or damage-associated molecular patterns, 
which induce the expression of pro-inflammatory cytokines results in cellular dysfunction 
that contributes to ALD. 
Multiple interventions targeting the innate immune system have emerged in 
treating ALD. These treatments could include antibodies against pro-inflammatory 
cytokines, use of anti-inflammatory cytokines, or suppression of alcohol-induced 
epigenetic regulators of innate immunity. Stimulation of innate immunity is increasingly 
recognized to play an important role in the pathogenesis of ALD, while the contribution 
of adaptive immunity has received less attention 69.  
Inflammasome activation is an important component of the liver pathophysiology 
in ALD 70,71. The NLRP3 inflammasome (an intracellular protein complex consisting of 
NLRP3, apoptosis-associated speck protein with caspase activation and recruitment 
domain (ASC), and caspase-1) is one of the most studied inflammasomes. The NLRP3 
inflammasome requires both Signal 1 (Pathogen-associated molecular patterns, PAMPs) 
and Signal 2 (Danger-associated molecular patterns, DAMPs) for its full activation. The 
activation of caspase-1 enables the cleavage of pro-interleukin (IL)-1β to form active IL-




1.4 Antimicrobial Peptides, Cathelicidin, and Their Roles in Liver Diseases 
One of most important mechanisms maintaining gut microbiota homeostasis is 
antimicrobial peptides (AMPs)-mediated regulation. Intestinal goblet cells-produced 
mucin forms the mucus layer, serving as the first defense against bacterial invasion into 
the mucosa. AMPs are produced in Paneth cells, enterocytes, intestinal epithelial cells 
and macrophages. They form a central part of the innate immune system to counter 
microbial infections 73 and inhibit the overgrowth of pathogenic bacteria in gut lumen 
74,75, serving as intrinsic regulators of gut eubiosis.  
Previous studies have demonstrated the critical role of AMPs in the pathogenesis 
of ALD 61,76,77. Lack of intestinal epithelial cell-derived Reg3β or Reg3γ (regenerating 
islet-derived (REG)-3 lectins) exacerbated alcohol-induced dysbiosis and ALD, while 
overexpression of Reg3g attenuated ALD 76.  The Paneth cell-produced antimicrobial 
peptide family, α-defensins, is another important group of antimicrobial peptides. 
Although expression of α-defensin 5 did not differ significantly in mice fed alcohol 
intragastrically for 3 weeks 61, dysfunction of α-defensin 5 exacerbated alcohol-induced 
luminal and mucus-associated microbiota alterations and resulted in a severe liver injury, 
while zinc supplementation increased α-defensin 5 production and reduced ALD 78.  
Alcohol consumption also decreased other types of antimicrobial peptides. Our 
previous studies showed a decreased expression of intestinal CRAMP (Cathelicidin-
associated antimicrobial peptide) in mouse models of ALD, and that treatment with 
probiotics improved gut microbiota homeostasis and restored intestinal CRAMP 
expression in mice 79,80.  
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CRAMP is a mouse ortholog of LL-37, the only member of the human 
cathelicidin family 81 (Figure 1.3). LL-37/CRAMP has piqued great research interest for 
the dual role in modulating microbiota and immune response 82 (Figure 1.4) in several 
infectious disease and inflammatory bowel disease (IBD) 83-85. Wild-type (WT) mice 
cohoused with Camp-/- (CRAMP knockout) mice had markedly increased sensitivity to 
dextran sulfate sodium (DSS)-induced colitis, with a skewed composition of fecal 
microbiota 86. Previous studies showed that cathelicidins also serve as immune 
modulators in metabolic diseases. CRAMP produced by β-cells in the pancreatic islets 
induces regulatory macrophages and DCs (dendritic cells), generating the pancreatic 
regulatory T cells; whereas in the absence or deficiency of CRAMP, the macrophages 
and dendritic cells exhibit an inflammatory profile, thus generating diabetogenic T cells, 
which attack the pancreas and destroy the insulin-secreting cells, leading to decreased 
insulin production and type1 diabetes 87. Notably, the production of CRAMP in the 
pancreas is controlled by gut derived short chain fatty acids (SCFAs), which 
demonstrates the importance of gut microbiota in CRAMP regulation 87. More recently, 
studies have shown that CRAMP suppresses hepatic steatosis in high fat diet-treated mice 




Figure 1.3 The cathelicidin family.  
  
Figure 1.4 Dual role of cathelicidin. 
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Inflammasome activation is an important component of the liver pathophysiology 
in ALD 70,71. The NLRP3 inflammasome (an intracellular protein complex consisting of 
NLRP3, apoptosis-associated speck protein with caspase activation and recruitment 
domain (ASC), and caspase-1) is one of the most studied inflammasomes. The NLRP3 
inflammasome requires both Signal 1 (Pathogen-associated molecular patterns, PAMPs) 
and Signal 2 (Danger-associated molecular patterns, DAMPs) for its full activation. The 
activation of caspase-1 enables the cleavage of pro-interleukin (IL)-1β to form active IL-
1β, which can then be secreted out and bind to the IL-1 receptor to induce inflammation 
72. LL-37 prevented the TLR-4 mediated pro-inflammatory signaling by inhibiting the 
binding of LPS to the CD14/TLR-4 complex and by promoting LPS degradation by 
lysosomes 89-91. However, whether LL-37/CRAMP is involved in the regulation of 
inflammasome activation in ALD remains unclear.  
Alcohol consumption and obesity work synergistically to promote ALD. A recent 
study showed that feeding mice with short- or long-term HFD plus a single ethanol binge 
synergistically increased the serum and hepatic free fatty acid levels, chemokine CXCL-1 
expression and exaggerated neutrophil infiltration in the liver, eventually leading to 
severe liver injury 45. Human cathelicidin LL-37 and mouse CRAMP have been 
demonstrated to act as a chemoattractant to neutrophils and inflammatory monocytes, 
through the chemokine receptor, CXCR2 92,93. This suggests a potential role of CRAMP 
in regulating neutrophil infiltration and chemokine expression in alcohol-induced liver 




1.5 Specific Aims & Significance 
Chronic liver disease either caused from alcohol abuse and high fat/high fructose 
diet place a heavy burden worldwide economically and sociologically. Although almost 
95% of heavy drinkers develop the fatty liver, simple steatosis, only up to 40% of this 
population develops more severe forms of ALD. Several risk factors, including gut 
microbiota changes, contribute to this disease progression. AMPs that are predominantly 
expressed in the enterogastric tract play an important role in regulating bacteria growth 
and the translocation of bacteria and their products, mainly LPS. AMPs such as 
cathelicidin, LL-37 in human and CRAMP in mouse have piqued great research interest 
regarding their dual role in gut microbiota regulation as well as immune modulation. 
There were two specific aims in this dissertation. The first aim of this dissertation was to 
investigate whether CRAMP protects the liver from alcohol-induced injury and whether 
the effect is mediated through regulation of gut microbiota and inflammasome activation 
inhibition. The second aim was to investigate the role of CRAMP, a chemoattractant for 
neutrophil infiltration, in binge alcohol-induced liver injury in HFD-fed mice.  
This dissertation aimed to investigate the role of CRAMP/LL-37 in alcohol-
related liver disease in different animal models. The preconditioned fatty liver and 
impaired intestinal barrier function is of high clinical relevance as a large portion of 
patients with chronic liver disease also develop diabetes, obesity and have impaired gut 
barrier function. The unique properties of CRAMP in terms of the expression (CRAMP is 
expressed in multiple organ and diverse cell types) and function (antimicrobial activity, 
immune modulator and chemoattractant) gives great novelty and value to the present 




CHAPTER 2 ANTIMICROBIAL PEPTIDE CATHELICIDIN ALLEVIATES 
ALCOHOLIC LIVER DISEASE THROUGH INHIBITING LPS AND URIC ACID-
INDUCED INFLAMMASOME ACTIVATION IN MICE 
 
 
2.1 Introduction   
Patients with alcohol associated liver disease (ALD) have high morbidity and 
mortality in its severe forms 13,94. Altered gut microbiota has been identified as one of the 
major features in different forms of ALD 46. Alcohol consumption causes dysbiosis and 
“leaky gut”, which allows the translocation of bacteria and their products through the 
portal vein into the liver, resulting in damage to the liver cells and the development of 
hepatic steatosis and liver injury through the toll-like receptor 4 (TLR4)-mediated 
pathway 48,49.  
One of the most important mechanisms maintaining gut microbiota homeostasis is 
antimicrobial peptides (AMPs)-mediated regulation. AMPs are produced in Paneth cells, 
enterocytes, intestinal epithelial cells and macrophages, and form a central part of the 
innate immune system to counter microbial infections 73 and inhibit the overgrowth of 
pathogenic bacteria in the gut lumen 74,75. Previous studies have demonstrated the critical 
role of AMPs in the pathogenesis of ALD 61,76,77. Lack of intestinal epithelial cell-derived 
regenerating islet-derived (REG)-3 lectins, Reg3β or Reg3γ, exacerbated alcohol-induced 
dysbiosis and ALD, while overexpression of Reg3g attenuated ALD 76.  Recent work 
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further showed that alcohol-induced α-defensin dysfunction exaggerated endotoxin 
translocation and liver damage 78. In addition to Reg3 lectins and defensins, cathelicidins 
are a major AMPs family. LL-37 is the sole member of the human cathelicidin family, 
and has a murine ortholog, cathelicidin-related antimicrobial peptide (CRAMP). LL-
37/CRAMP has stimulated great research interest because of its dual role in modulating 
microbiota and immune responses in several infectious diseases and in inflammatory 
bowel disease (IBD) 83-85. Wild-type (WT) mice cohoused with Camp-/- (CRAMP 
knockout) mice had markedly increased sensitivity to dextran sulfate sodium (DSS)-
induced colitis, with a skewed composition of fecal microbiota 86. CRAMP deficiency 
exacerbated type 1 diabetes through the dysregulation of β-cell immunity 87. Notably, the 
production of CRAMP in the pancreas is controlled by gut derived butyric acid, implying 
the importance of gut microbiota in CRAMP regulation 87.  
Inflammasome activation is an important component of the liver pathophysiology 
in ALD 70,71. The NLRP3 inflammasome (an intracellular protein complex consisting of 
NLRP3, apoptosis-associated speck protein with caspase activation and recruitment 
domain (ASC), and caspase-1) is one of the most studied inflammasomes. The NLRP3 
inflammasome requires both Signal 1 (Pathogen-associated molecular patterns, PAMPs) 
and Signal 2 (Danger-associated molecular patterns, DAMPs) for its full activation. The 
activation of caspase-1 enables the cleavage of pro-interleukin (IL)-1β to form active IL-
1β, which can then be secreted and bind to the IL-1 receptor to induce inflammation 72. 
LL-37 prevented the TLR-4 mediated pro-inflammatory pathway by inhibiting the 
binding of LPS to the CD14/TLR-4 complex and by promoting the LPS degradation by 
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lysosomes 89-91. However, whether LL-37/CRAMP is involved in the regulation of 
inflammasome activation in ALD remains unclear.  
Our previous studies showed a decreased expression of intestinal CRAMP in 
mouse models of ALD, and the treatment with probiotics improved gut microbiota 
homeostasis and restored intestinal CRAMP expression in mice 79,80. In the current study, 
the hypothesis that CRAMP protects the liver from alcohol-induced injury through the 
regulation of inflammasome activation was tested. CRAMP deficiency exacerbates, while 
exogenous CRAMP peptide alleviates, alcohol-induced liver injury through inhibition of 
inflammasome activation by decreasing LPS function and uric acid (UA) production. 
 
2.2 Materials and Methods 
2.2.1 Animals 
Camp-/- mice were purchased from Jackson laboratory (#017799) and breed to 
obtain sufficient colonies for experiment. Camp-/- male mice at the age of 8-10 weeks 
were used with their age-matched littermates WT mice (C57BL/6). Mice were 
maintained at 22°C with a 12h light/dark cycle and had free access to a normal chow diet 
and water. Mice were fed the Lieber DeCarli diet containing 5% alcohol (w/v) (Alcohol-
fed, AF) or isocaloric maltose dextrin (Pair-fed, PF). For the AF groups, mice were 
initially fed the control Lieber-DeCarli liquid diet (Bio-Serve, Flemingtown, NJ) for 5 
days to acclimate the mice to the liquid diet. The content of alcohol in the liquid diet of 
the AF groups was gradually increased from 1.6% (w/v) to 5% (w/v) in the first 6 days 
and remained at 5% for the subsequent 24 days. Mice in PF group were fed isocaloric 
Maltose Dextrin substituted for alcohol in the liquid diet for 24 days. To account for the 
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reduced food consumption of ethanol-fed mice, pair-fed mice were given the volume of 
diet consumed by their ethanol-fed counterparts in the previous day. On Day 24, 6 hours 
before harvesting, a bolus of EtOH (5 g/kg body weight) was given to alcohol-fed mice 
by gavage, while mice in PF groups received a gavage of maltose dextrin. The 38-amino 
acid CRAMP peptide (H-ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE-
OH) was synthesized (Peptides International, Louisville, KY) and 100 μg CRAMP 
peptide in 100 μl saline was injected to alcohol-fed mice intraperitoneally (I.P.) once 
daily for 3 days prior to the conclusion of the feeding period. Serum and tissue samples 
were collected for analysis. All mice were treated according to the protocols reviewed 
and approved by the Institutional Animal Care and Use Committee of the University of 
Louisville. 
 
2.2.2 Human Study 
2.2.2.1 Alcohol-associated Hepatitis Study 
Forty-seven male and female acute alcohol-associated hepatitis (AAH) patients (31 
severe patients with Model for End‐Stage Liver Disease [MELD] score ≥20; and 16 
moderate patients with MELD score <20) plus 11 healthy volunteers were included in this 
clinical study. This investigation was conducted as one of the aims of a large national 
multisite clinical trial (clinicaltrials.gov: NCT01809132) sponsored by the National 
Institute on Alcohol Abuse and Alcoholism (NIAAA). Patients were 21 to 66 years of age. 
Healthy controls (HCs) were of similar age and did not have liver disease or any other 
relevant disease conditions (heart, kidney, lung, neurologic or psychiatric illness, sepsis), 
and none of them showed any signs of a pro-inflammatory state 95. 
20 
 
2.2.2.2 AUD Study 
Plasma samples from forty-eight male and female heavy drinking alcohol use 
disorder (AUD) patients from NIAAA were analyzed. Patients were grouped by serum 
alanine aminotransferase (ALT) levels (as a marker of liver injury) as AUD without ALD 
(ALT≤40 U/L, 7M/8F) and AUD with ALD (ALT>41U/L, 27M/6F). Demographics, 
drinking history (using lifetime drinking history [LTDH], and timeline follow back [TLFB] 
for the past 90 days) assessments, and serum uric acid were evaluated. All clinical 
laboratory assays were performed by the Department of Laboratory Medicine at NIH 
Bethesda MD per its guideline. Plasma IL-1β levels were determined by multianalyte 
chemiluminescent detection using Mulliplex kits (Millipore, Billerica, MA) on the 
Luminex (Luminex, Austin, TX) platform based on the manufacturers’ instructions. 
2.2.2.3 Liver Explants 
Nine liver tissues (explants) from patients with severe AH were obtained from the 
Resource Center at Johns Hopkins University (n = 6 active drinkers, mean age 44 ± 10.1, 
2 female and 4 male patients) and University of Louisville Hospital (n = 3, mean age 57 ± 
18.9, one female and two male patients who were abstinent for more than 6 months). Five 
non-AH liver samples were also acquired from the Resource Center at Johns Hopkins 
University 96. 
All studies were approved by the respective Institutional Review Boards and 
written consent was obtained from all participants. All subjects consented to having their 
samples used in further research studies. 
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2.2.3 Cell Culture 
2.2.3.1 Macrophage 
RAW264.7 (mouse macrophage cell line) cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM, Invitrogen), supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin and were maintained at 37 °C and 5% CO2. 
Bone marrow-derived cells were isolated from WT and Camp-/- mice as previously 
described 97. Isolated cells were then cultured in modified DMEM medium with 
macrophage colony-stimulating factor (M-CSF), which is a cytokine that directs cell 
differentiation into macrophages. The bone marrow-derived macrophages (BMDM) were 
exposed to varying doses of synthetic CRAMP peptide for 2 hours prior to LPS stimulation 
(Escherichia coli 0111: B4, Sigma-Aldrich, St. Louis, MO) at 100 ng/ml for 4 hours. For 
UA-induced signal 2 transduction in inflammasome activation, RAW264.7 cells and 
BMDMs were primed with LPS at 500 ng/ml for 4 hours, then LPS was washed out with 
phosphate buffered saline (PBS), before treating the cells with UA (Uric acid, Sigma, St. 
Louis, MO) at 500 µM and CRAMP peptide for 4.5 hours in FBS-free DMEM culture 
medium. The CRAMP peptide was used at 1 µg/ml or 10 µg/ml in macrophage cell culture. 
Cell viability was not affected by LPS or CRAMP treatment at the doses used in the 
experiments. For ATP and LPS-induced inflammasome activation in RAW264.7 cells, 
ATP (Adenosine 5-triphosphate, Sigma, St. Louis, MO) was added at the concentration of 
50 mM and cells were cultured for additional 30 mins after being primed with LPS (100 
ng/ml) for 4 hours.  
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2.2.3.2 Hepatocyte and siRNA Transfection 
Hepa1-6 (mouse hepatoma cell line) cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM, Invitrogen), supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin and were maintained at 37 °C and 5% CO2. 
Desferrioxamine (DFO) (Sigma, St. Louis, MO) at a concentration of 200 µM was used 
to treat the cells for 20 hours. For the ethanol treatment study, Hepa1-6 cells were treated 
with 400 mM ethanol (Decon Labs, King of Prussia, PA) for 4 hours. Knockdown of 
Camp in Hepa1-6 cells was achieved by siRNA transfection according to the 
manufacturer’s protocol (Horizon, Waterbeach, United Kingdom). The siRNA targeting 
Camp (siRNA-Camp) (siGENOME Mouse Camp siRNA, SMARTPool, 5 nmol) and 
non-targeting control siRNA (siRNA-NT) (siGENOME Non-Targeting siRNA Control 
Pool #2) were suspended in siRNA buffer (5X siRNA buffer, Horizon) to the desired 
concentration. Hepa1-6 cells were seeded in 48-well plates the day before transfection. 
On transfecting day, siRNA and transfection reagent Lipofectamine (Lipofectamine™ 
RNAiMAX Transfection Reagent, ThermoFisher, Waltham, MA) were prepared 
separately in reduced serum medium (Opti-MEM Reduced Serum Medium, 
ThermoFisher, Waltham, MA) and mixed followed by an incubation at room temperature 
for 20 mins. The transfection medium was then added into the wells after removal of 
culture medium. Cells were continued in the transfection medium for 16 hours and the 
transfection medium was replaced with complete medium for an additional 8 hours 
before treatment.  
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2.2.4 ALT and AST Measurements 
Serum activity levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were determined using standard kits (Thermo Scientific, 
Waltham, MA).  
 
2.2.5 Histological Analysis 
2.2.5.1 Paraffin Embedded Liver Tissue 
Liver tissues were collected and fixed in 4% paraformaldehyde and embedded in 
paraffin. The paraffin-embedded tissue blocks were then sliced at 5 µm thickness on a 
microtome and floated in a 40°C water bath containing distilled water. Sections were then 
transferred onto glass slides. Slides were dried overnight and stored at room temperature 
until ready for use. Before staining, slides were deparaffinized with Citrisolv (Decon, 
King of Prussia, PA) and rehydrated by immersing in graded ethanol solutions. 
H&E Staining Hematoxylin and eosin (H&E) were used to stain the nuclear and 
cytoplasm components, respectively. After staining, sections were then dehydrated 
through graded alcohol, cleared in Citrisolv and then mounted with Cytoseal Xyl 
(Thermo Scientific, Waltham, MA) and observed by microscopy. 
CAE Staining Infiltration of neutrophils in the liver was assessed by chloroacetate 
esterase (CAE) staining according to manufacturer’s instructions (Naphthol AS-d 
Chloroacetate Kit, Sigma, St. Louis, MO). Briefly, liver sections were incubated in a 
solution of naphthol AS-D chloroacetate. The naphthol AS-D chloroacetate is 
enzymatically hydrolyzed by “specific esterase” in neutrophils, liberating a free naphthol 
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compound. This then couples with a diazonium compound, forming highly colored 
deposits at sites of enzyme activity that can be visualized under microscopy. 
TUNEL Staining Apoptosis was detected via terminal deoxynucleotidyl transferase 
biotin-dUTP nick end labeling (TUNEL) staining according to the manufacturer’s 
instructions (Millipore, Temecula, MA). In brief, the apoptotic cells in situ were 
identified by using terminal deoxynucleotidyl transferase (TdT) to transfer biotin-dUTP 
to the free 3’-OH of cleaved DNA. The biotin-labeled cleavage sites were then visualized 
by reaction with fluorescein conjugated avidin (avidin-FITC).  
F4/80 Immunohistochemistry Following deparaffinization, antigen retrieval was 
performed on slides in 10mM citrate buffer (pH6.0) for 20 min at 95ºC. Blocking buffer 
containing 1% bovine serum albumin (BSA) (Sigma, St. Louis, MO) was added onto the 
slides and the slides were incubated in a humidified chamber at room temperature for 1 
hour, for the blocking of non-specific antibody binding. Sections were then incubated 
with primary antibody F4/80 (Abcam, Cambridge, UK) and AlexaFluor-conjugated 
secondary antibodies (Invitrogen, Carlsbad, CA). DAPI (Invitrogen, Carlsbad, CA) was 
used for nuclei counterstain. 
2.2.5.2 Frozen Liver Tissue 
Liver tissues were immersed with optimal cutting temperature compound (OCT) 
and stored frozen in liquid nitrogen immediately after harvesting.  
Oil Red O Staining Frozen sections were cut at 8μm to the slides and air dried. The slides 
were rinsed with 60% isopropanol and then stained with freshly prepared Oil Red O 
working solution for 15mins and rinsed again with 60% isopropanol. Nuclei were lightly 
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stain using haematoxylin for 45 seconds followed with 2 times rinse with distilled water. 
Slides were then mounted in aqueous mount and observed by microscopy.  
DHE Staining Reactive oxygen species (ROS) accumulation in the liver was examined by 
dihydroethidium (DHE) staining. In brief, cryostat sections of liver were incubated with 5 
μmol/L DHE (Molecular Probes, Eugene, OR) for 30 min at 37°C in the dark. 
Nonfluorescent dihydroethidium is oxidized by ROS to yield the red fluorescent product, 
ethidium, which binds to nucleic acids and stains the nucleus with bright fluorescent red. 
The red fluorescence was examined under confocal microscopy and the intensity of 
fluorescence was quantified using Image J. 
 
2.2.6 Lipid Accumulation 
Liver tissues were homogenized in 50 mM NaCl (Sigma, St. Louis, MO) solution 
in distilled water. The homogenates were then used for lipid extraction using methanol 
(Fisher chemical, Fair Lawn, NJ) and chloroform (Fisher chemical, Fair Lawn, NJ). Liver 
triglyceride (TG) and free fatty acid (FFA) levels were determined using commercial kits 
according to manufacturer’s instructions. (Thermo Scientific, Waltham, MA). 
 
2.2.7 RNA Isolation and Real-time RT-PCR 
The mRNA levels were assessed by real-time polymerase chain reaction (PCR). 
In brief, the total RNA was extracted from liver, colon, spleen, epididymal white adipose 
tissue (eWAT) and lung tissue with Trizol according to manufacturer’s protocol (Life 
Technologies, Carlsbad, CA) and reverse-transcribed using cDNA supermix (QuantaBio, 
Beverly, MA). Quantitative real-time PCR was performed on an ABI 7500 real-time PCR 
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thermocycler, whereas SYBR green PCR Master Mix (Applied Biosystems, Foster City, 
CA) was used for real-time PCR analysis. The relative quantities of target transcripts 
were calculated from duplicate samples after normalization of the data against the 
housekeeping genes, 18S (mouse) or ACTB (gene name for human Beta-Actin). Relative 
mRNA expression was calculated using the Ct method. The primer pairs used are listed in 
Table 2.1. 
 
Table 2.1 List of Primers 
Gene 
name 













Camp TCTCTACCGTCTCCTGGACCTG CCACATACAGTCTCCTTCACTCG 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
Il-1β TTCATCTTTGAAGAAGAGCCCAT TCGGAGCCTGTAGTGCAGTT 
Il-6 TGGAAATGAGAAAAGAGTTGTGC CCAGTTTGGTAGCATCCATCA 
Tnf-α AGGCTGCCCCGACTACGT GACTTTCTCCTGGTATGAGATAGCAAA 
Il-18 AAAGTGCCAGTGAACCC TTTGATGTAAGTTAGTGAGAGTGA 
Mcp-1 ACCACAGTCCATGCCATCAC TTGAGGTGGTTGTGGAAAAG 
Il-10 CCCTTTGCTATGGTGTCCTT TGGTTTCTCTTCCCAAGACC 
Lbp CAAACTCTGCCAGTCACA GGACATTGGCACCCAAGT 
Cd14 TGAGTATTGCCCAAGCACACT GTAACTGAGATCCAGCACGCT 








Nrf2 CGAGATATACGCAGGAGAGGTAAGA GCTCGACAATGTTCTCCAGCTT 
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Gsr GCTATGCAACATTCGCAGATG AGCGGTAAACTTTTTCCCATTG 
Cat TGAGAAGCCTAAGAACGCAATTC CCCTTCGCAGCCATGTG 
Gstp1 TGGGCATCTGAAGCCTTTG GATCTGGTCACCCACGATGAA 
Gpx1 GAAGAACTTGGGCCATTTGG TCTCGCCTGGCTCCTGTTT 
Uox GAAGTGGAATTTGTCCGAACTGG CGAAGTTGCCACCTCTTTGAT 
Xdh ATGACCGCCTTCAGAACAAGA TGTCACAGCAACATGATGCAA 







CAGCACGTGAAGGTGGGGAC CCTTGCGGTTGGCTTCAGAT    
Vdr GAGGTGTCTGAAGCCTGGAG ACCTGCTTTCTGGGTAGGT 
Hif-1α GAAATGGCCCAGTGAGAAAA CTTCCACGTTGCTGACTTGA 
P2x7 TGGAACCCAAGCCGACGTTGA CTCGGGCTGTCCCCGGACTT 
Fpr2 CACAGGAACCGAAGAGTGTAAG CACCATTGAGAGGATCCACAG 
Cxcr-2 CACCGATGTATACCTGCTGA ACGCAGTACGACCCTCAAAC 
Vcam-1 AATGGGAATCTACAGCACCTTT ATATCCGTATCCTCCAAAAACT 
Ly6G TGCGTTGCTCTGGAGATAGA CAGAGTAGTGGGGCAGATGG 
Cxcl-2 ATCCAGAGCTTGAGTGTGACG GTTAGCCTTGCCTTTGTTCAG 
 
2.2.8 Immunoblots 
Liver and spleen tissues or cultured cells were lysed in radioimmunoprecipitation 
assay (RIPA) buffer (Thermo Scientific, Waltham, MA). Lysed samples were then 
centrifuged for 15 min at 12000 x g at 4°C, and the supernatants were collected. The 
protein concentration was measured by using a bicinchoninic acid assay (BCA) assay kit 
(Pierce, Thermo Scientific, Waltham, MA). Sample aliquots were boiled for 5 min and 
equal protein amounts (usually 35-50 μg) were separated by SDS-PAGE. Proteins were 
then transferred to a nitrocellulose membrane. Blots were blocked for 1 h in Tris-buffered 
saline/Tween 20 (TBST buffer) (10 mM Tris–HCl, pH 8.0, 150 mM NaCl, and 0.05% 
Tween 20) containing 5% nonfat dry milk and incubated overnight at 4 °C with the 
different primary antibodies diluted (typically 1:1000) in TBST buffer containing 3% 
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BSA. Blots were then incubated in horseradish peroxidase (HRP)-conjugated secondary 
antibodies (typically 1:5000 dilution) for 1 h at room temperature. Following treatment 
with supersignal west HRP substrate (MilliporeSigma, Billerica, MA), protein bands 
were detected by a ChemiDoc Molecular Imager (Bio-Rad, Hercules, CA). 
Quantification for the bands was performed using ImageJ software (National Institutes of 
Health) and normalized to β-actin or GAPDH. The following primary antibodies were 
used: CRAMP (Abcam, Cambridge, UK), NLRP3 (Cell signaling, Danvers, MA), 
Caspase-1 pro and cleaved (Abcam, Cambridge, UK), ASC (Cell signaling, Danvers, 
MA), pro IL-1β (Cell signaling, Danvers, MA), Cleaved IL-1β (Cell signaling, Danvers, 
MA), β-actin (Cell signaling, Danvers, MA), GAPDH (Cell signaling, Danvers, MA). 
 
2.2.9 ELISA 
Protein levels of human LL-37 in patient serum were determined using human 
LL-37 enzyme-linked immunosorbent assay (ELISA) kit (Hycult Biotech, Wayne, PA). 
Mouse CRAMP protein levels in serum were determined using mouse Cathelicidin 
ELISA kit (MyBiosource, San Diego, CA). IL-1β levels in mice serum and cell culture 
medium were determined using IL-1β ELISA kit (Thermo Scientific, Waltham, MA) 
according to the manufacturers’ instructions, respectively.  
 
2.2.10 Endotoxin Assay 
Chromogenic Limulus Amebocyte Lysate (LAL) endotoxin kit was used to 
determine serum LPS levels according to the manufacturer’s protocol (Lonza, Basel, 
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Switzerland). All material used for harvesting blood and measuring endotoxin was 
pyrogen free. 
 
2.2.11 LPS-binding Assay 
LPS-binding assay was performed as previously described 89. Briefly, RAW264.7 
cells (1x106 cells/ml) were incubated with FITC-conjugated LPS (1µg/ml) in the absence 
or presence of CRAMP peptide (0.1, 0.5, 1, 2, 5, 7.5, 10 µg/ml) in DMEM containing 
10% FBS for 15mins at 37 °C. Cells were then washed with PBS, and the binding of 
FITC-LPS was analyzed by flow cytometry (FACSCanto, BD, Franklin Lakes, NJ). The 
fluorescence intensity was determined and plotted as fold changes to FITC-LPS control. 
 
2.2.12 Serum ATP 
Serum adenosine triphosphate (ATP) level was assessed by a 
colorimetric/fluorometric assay kit according to the manufacturer’s protocol (Biovision, 
Milpitas, CA). Briefly, the phosphorylation of glycerol generates a colored product, 
which can be easily quantified by colorimetric methods by reading endpoint absorbance 
value at λ = 570 nm. 
 
2.2.13 Serum Uric Acid 
The levels of uric acid (UA) in mouse serum samples were determined using a 
commercial UA assay kit (Abcam, Cambridge, UK) according to the manufacturer’s 
protocol. UA level was measured using a colorimetric (at λ = 570 nm) method. 
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2.2.14 Serum XO Activity 
Serum and hepatic xanthine oxidase (XO) activity were determined using a 
commercial colorimetric kit (Biovision, Milpitas, CA) according to the manufacturer’s 
protocol. Diluted serum samples and liver lysates (collected supernatant only) were used 
for the assay. In the assay, XO oxidizes xanthine to hydrogen peroxide (H2O2) which 
reacts stoichiometrically with OxiRed probe to generate color (at λ = 570 nm). Since the 
color or fluorescence intensity is proportional to XO content, the XO activity can be 
accurately measured. 
 
2.2.15 Gut Microbiota Analysis 
Fecal samples were collected at the harvest from mouse colon and stored at -
80°C. Bacterial genomic DNA was then extracted from fecal samples using the MO BIO 
Powersoil DNA Extraction Kit (Carlsbad, CA). Genomic DNA samples were then 
analyzed for 16S rRNA Gene Sequencing on the 454 FLX-titanium Platform as 
previously described 79.   
 
2.2.16 Bacterial Cultures 
E. coli (Escherichia coli), Bacillus subtilis 22 CP-1 were cultured in lysogeny 
broth (LB) (Sigma-Aldrich, St. Louis, MO), while probiotic Lactobacillus rhamnosus GG 
(LGG) was cultured in MRS broth (Sigma-Aldrich, St. Louis, MO), and Listeria was 
cultured in Brain Heart Infusion (BHI) medium (ThermoFisher, Waltham, MA). All 
bacteria strains were cultured with or without the addition of CRAMP peptide at the 
concentration of 3 µg/ml. Bacteria cultured in 15ml sterilized tubes were incubated at 
37°C on an incubation-shaker. Bacterial growth was monitored by measuring optical 
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density λ = 600 nm (OD600). OD600 values of bacterial culture were recorded at 
different time points with 30-minute intervals for a total of 6 hours after CRAMP peptide 




Statistical analyses were performed using the statistical computer package, 
GraphPad Prism version 6, (GraphPad Software Inc., San Diego, CA, USA), MS Excel 
2016 (Microsoft Corp., Redmond, WA) or SPSS 26.0 (IBM, Chicago, IL). Results are 
expressed as means ± standard error of the mean (SEM). Statistical comparisons were 
made using two-way analysis of variance (ANOVA) with Tukey’s post hoc test or 
Student’s t-test, where appropriate. Differences were considered to be significant at 
p<0.05. Columns with different letters are statistically different from each other, or 
significance may be noted as *p<0.05, **p<0.01, ***p<0.001 between groups.  
 
2.3 Results 
2.3.1 Dysregulated Cathelicidin in Alcohol Fed Mice and in Patients with ALD  
Previous studies in our groups showed that ileal CRAMP mRNA expression was 
decreased in mice treated with binge alcohol or on chronic alcohol feeding for 4 weeks 
79,80. To further evaluate CRAMP tissue expression in response to alcohol feeding, the 
mRNA levels of Camp (gene name for mouse CRAMP) in various tissues of the mice fed 
alcohol were analyzed. CRAMP is highly expressed in the spleen and epididymal white 
adipose tissue (eWAT) on basal level (Figure 2.1A). Mice received the 24 days chronic 
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alcohol feeding plus 1 binge at the end of feeding (24D+1B, binge-on-chronic alcohol-
feeding paradigm). Alcohol feeding significantly increased Camp mRNA expression in 
the liver and spleen, and decreased expression in the lung tissue, while no change was 
found in the eWAT and in the colon (Figure 2.1B). Interestingly, spleen CRAMP protein 
was decreased by alcohol, while liver levels of CRAMP were increased (Figure 2.1C). 
There was no change in serum CRAMP levels in mice fed alcohol (Figure 2.1D). 
Similarly, in patients with ALD, the hepatic mRNA levels of LL-37 (gene name CAMP) 
were elevated compared to healthy controls (Figure 2.1E). However, serum LL-37 
protein levels were decreased in ALD patients (Figure 2.1E). LL-37 is transcriptionally 
regulated by hypoxia-inducible factor 1α (HIF-1α) 79,98 and vitamin D receptor (VDR) 
99,100. Analyzing the expression of HIF-1α and VDR revealed that hepatic CAMP mRNA 
was positively correlated with mRNA levels of HIF1A and VDR (Figure 2.1F), indicating 









(A) Differential expression of Camp (gene name of mouse CRAMP) in the liver, colon, 
spleen, eWAT and lung. (B) Alcohol-induced changes in Camp expression in different 
organs. (C) Alcohol-induced CRAMP protein level changes in the liver and spleen tissue 
by immunoblotting. (D) Serum CRAMP level. Data are expressed as mean ± SEM, (n≥5). 
(E) Serum LL-37 (upper panel) and hepatic CAMP (gene name of human LL-37) (lower 
panel) level in ALD patients and healthy controls (HC). Data are expressed as mean ± 
SEM, (n≥5). (F) Hepatic CAMP expression correlates with HIF1A and VDR expression 
in ALD patients (n=14). *p<0.05, **p<0.01, ***p<0.001.   
 
2.3.2 CRAMP Deficiency Exacerbated Alcohol-induced Liver Steatosis and Injury  
To determine the role of CRAMP in ALD, Camp-/- and WT mice were fed alcohol 
in a binge-on-chronic model (24D+1B). Alcohol consumption resulted in increased levels 
of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in both WT and 
Camp-/- mice, with more pronounced elevations being found in Camp-/- mice (Figure 
2.2A). Alcohol feeding increased hepatic fat accumulation in both WT and Camp-/- mice, 
but much more severe macrosteatosis was found in Camp-/- mice (Figure 2.2B, upper 
panel), and this was then confirmed by Oil Red O staining of frozen liver sections (Figure 
2.2B, middle panel). Importantly, the distribution of lipid droplets in the livers of Camp-/- 
and WT mice was zonally distinct from each other (Figure 2.2C). Enhanced hepatic fat in 
Camp-/- mice was further confirmed by the measurement of hepatic triglyceride and free 
fatty acid contents (Figure 2.2D). Moreover, alcohol exposure induced more hepatic 
apoptosis in Camp-/- mice, shown as an increased number of terminal deoxynucleotidyl 
transferase biotin-dUTP nick end labeling (TUNEL)-positive cells (Figure 2.2B, lower 
35 
 
panel). These results suggest that alcohol feeding exacerbates liver steatosis, injury and 




Figure 2.2 CRAMP deficiency exacerbates ethanol-induced liver injury, steatosis 
and hepatic cell death.  
(A) Serum transaminases AST and ALT. (B) Representative photomicrographs of liver 
sections with H&E (hematoxylin and eosin) staining (200x) (upper panel), Oil-red O 
staining (200x) (middle panel) and TUNEL-positive cells staining (100x) (lower panel). 
Black arrows: apoptotic bodies. (C) Zonal distribution of alcohol-induced hepatic fat 
accumulation. CV: central vein; PT: portal tract; From CV to PT: Liver zones 3, 2, 1. (D) 
Hepatic triglycerides and free fatty acids in WT and Camp-/- mice. Data are expressed as 
mean ± SEM, (n≥8). *p<0.05, **p<0.01, ***p<0.001.   
 
2.3.3 Camp-/- Mice Had Dysbiosis in Response to Alcohol Feeding 
Gut bacterial dysbiosis has been well documented in mice with experimental 
ALD 61,101-103 and in patients with ALD 56,60,104,105. 16S rRNA sequence analysis showed 
distinctly different bacterial populations in the feces of WT and Camp-/- mice fed alcohol. 
At the phylum level (Figure 2.3A), Bacteroidetes decreased, while Firmicutes increased 
in Camp-/- mice fed alcohol, which agrees with previous studies 53,106,107. It is notable that 
there was a great expansion of Candidatus bacteria (TM7) in alcohol-fed Camp-/- mice, 
which was then confirmed by qRT PCR (Figure 2.3B). TM7 is one of the colitogenic 
microbiota phyla that have been shown to correlate with non-alcoholic fatty liver disease 
(NAFLD) 108,109. Total bacteria amount in fecal samples of WT and Camp-/- mice were 
comparable (Figure 2.3C). Of note, Akkermansia, a genus in the phylum 
Verrucomicrobia that is important in ALD 78,79, was increased in WT mice fed alcohol, 
while markedly decreased in the Camp-/- mice (Figure 2.3D). Genera analysis (Figure 
2.3E) showed that Bacteroides, which belongs to the Bacteroidetes phylum, completely 
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disappeared in Camp-/- mice fed alcohol. Thermophagus, another genus of Bacteroidetes, 
increased significantly in Camp-/- mice by 8-fold. Oscillibacter and Papillibacter in 
Ruminococcaceae families were decreased in Camp-/- mice, and have been reported to be 
decreased in cirrhotic patients 110. These results suggest that CRAMP may regulate 
microbiota homeostasis in ALD. Results from in vitro study further showed that CRAMP 
peptide, selectively inhibits bacterial growth. As depicted in Figure 2.3F, CRAMP 
peptide inhibited the growth of the pathogenic bacteria, Listeria and Escherichia coli (E. 
coli); however, notably, there was no effect on Bacillus subtilis 22 CP-1 and probiotic 























Figure 2.3 Camp-/- mice had dysbiosis in response to alcohol feeding.  
(A) CRAMP deficiency induced microbiota compositional changes on the phylum level 
as shown by metagenomic analysis using 16S rRNA sequencing in mouse fecal samples 
(n≥6). (B) Fold change of Saccharibacteria (TM7) bacteria abundance by alcohol feeding 
and CRAMP deficiency. (C) Total bacteria fold change by analyzing bacteria 16S rRNA 
using qRT PCR. (D) Akkermansia bacteria fold change. (E) CRAMP deficiency-induced 
bacteria abundance changes on the genera level. (F) Growth curve of Listeria, E. coli, 
Bacillus subtilis 22 CP-1 and probiotic LGG. Data are expressed as mean ± SEM (n≥4). 
*p<0.05, **p<0.01, ***p<0.001.  
 
2.3.4 Camp-/- Mice Had an Increased Hepatic Pro-inflammatory Response 
Inflammation is a hallmark of ALD in animal models and human subjects 28,111. Camp-/- 
mice had significantly increased mRNA levels of pro-inflammatory cytokines Il-1β, Il-6, 
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Tnfα and Il-18, and the chemokine, Mcp-1 (Figure 2.4A). Interestingly, Il-10, an anti-
inflammatory cytokine 112, was substantially lowered in the Camp-/- mice compared to the 
WT mice fed alcohol (Figure 2.4A). Histological analysis revealed increased levels of 
neutrophil infiltration and macrophage activation in the livers of Camp-/- mice (Figure 
2.4B). These results suggest that lacking CRAMP increased the pro-inflammatory 
response to alcohol in the liver and was associated with exacerbated neutrophil 




Figure 2.4 Increased pro-inflammatory response in the liver of Camp-/- mouse.  
(A) Hepatic cytokine and chemokine mRNA expression. (B) Representative 
photomicrographs of paraffin-embedded livers stained for CAE (200x) (upper panel) and 
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frozen liver tissue stained with immunofluorescence (IF) F4/80 antibody (100x) (lower 
panel). Black arrows: Infiltrated neutrophils; white arrows: F4/80 positive stained 
macrophages. Blue: DAPI counter stained nuclei; Red: F4/80. (C) Quantification of CAE 
(upper panel) and F4/80 IF (lower panel) staining. Data are expressed as mean ± SEM, 
(n≥8). *p<0.05, **p<0.01, ***p<0.001.  
 
2.3.5 CRAMP Deficiency Exacerbated Alcohol-induced IL-1β Production, Partially 
Through Enhancement of LPS Signaling 
Serum level of IL-1β was significantly increased in AF Camp-/- mice compared to 
the WT controls, indicating an inflammasome activation (Figure 2.5A), which requires 2 
signals for its full activation 113.  Serum endotoxin levels in both WT and Camp-/- mice 
were comparable (Figure 2.5B). To examine whether CRAMP is involved in LPS 
delivery and signal activation, the expression of LPS binding protein (LBP), CD14 and 
TLR4 was analyzed. Camp-/- mice had a significantly increased hepatic mRNA 
expression of LBP and CD14, and a slight trend of increase in TLR4 (Figure 2.5C), 
indicating an enhanced LPS activation. To further examine the role of CRAMP on LPS 
binding in macrophages, RAW264.7 cells were treated with synthetic CRAMP peptide in 
the presence of fluorescein isothiocyanate (FITC)-labeled LPS. CRAMP peptide 
inhibited LPS binding to macrophages in a dose-dependent manner (Figure 2.5D). The 
expression of genes involved in NLRP3 inflammasome activation was then analyzed. 
Hepatic Nlrp3 and Caspase-1 mRNA expression was increased in alcohol-fed Camp-/- 
mice compared to its WT controls. The active form of Caspase-1 protein, Caspase-1 p12, 
was significantly increased in Camp-/- mice (Figure 2.5E). Similar to the increased serum 
level of IL-1β protein, cleaved IL-1β was also elevated in the livers of Camp-/- mice 
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(Figure 2.5F). These findings suggest that the exacerbation of alcohol-induced IL-1β 
production in Camp-/- mice is likely through the loss of the inhibitory effect of CRAMP 






Figure 2.5 CRAMP deficiency exacerbated alcohol-induced IL-1β production 
partially through the enhancement of LPS signaling.  
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(A) Serum concentration of IL-1β analyzed by ELISA. (B) Serum endotoxin level. (C) 
Hepatic Lbp, Cd14 and Tlr-4 on mRNA level. (D) LPS binding activity shown as FITC 
intensity of FITC-conjugated LPS treated Raw 264.7 cells analyzed by flow cytometry. 
FITC-LPS: 1ug/ml. Significant digits represent the difference comparing FITC-LPS 
alone treated group. (E) Hepatic mRNA level of Nlrp3 and Caspase-1. (F) Representative 
bands of immunoblotting (left panel) and quantification (right panel) of molecules in 
inflammasome activation in whole liver lysates. Data are expressed as mean ± SEM, 
(n≥8). *p<0.05, **p<0.01, ***p<0.001.  
 
2.3.6 NLRP3 Inflammasome Activation and LPS-induced Inflammatory Cytokine 
Expression in Macrophages was Attenuated by Synthetic CRAMP Peptide 
Bone marrow-derived macrophages (BMDMs) from both Camp-/- and WT mice 
were treated with synthetic CRAMP peptide in the presence of LPS. LPS treatment 
significantly increased mRNA expression of Il-1β and Il-6 in BMDMs from Camp-/- mice 
compared to WT BMDMs (Figure 2.6A). Il-10 mRNA expression was also marginally 
increased by LPS in Camp-/- BMDMs (Figure 2.6A). CRAMP peptide treatment inhibited 
LPS-induced expression of inflammatory cytokines, including Il-1β, Il-18, Il-6 and Tnf-α. 
Il-10 mRNA expression was also inhibited by CRAMP peptide in Camp-/- BMDMs. The 
inhibitory effects of CRAMP peptide at the concentrations of 1 μg/ml and 10 μg/ml on 
LPS-induced cytokine expression are comparable, indicating a sensitization of Camp-/- 
BMDMs to CRAMP treatment in response to LPS stimulation (Figure 2.6A). 
Additionally, CRAMP peptide inhibited LPS-induced IL-1β in the cultural media in both 
WT and Camp-/- BMDMs (Figure 2.6B). To further confirm the observations in BMDMs, 
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these ex vivo experiments were extended to in vitro ones using RAW264.7 macrophages. 
CRAMP peptide significantly reduced the protein level of NLRP3 in a dose-dependent 
manner (Figure 2.6C). Pro-caspase-1 protein level was moderately reduced by CRAMP 
peptide. Remarkably, CRAMP peptide completely inhibited the pro-IL-1β protein 
expression by LPS stimulation at both high and low doses (Figure 2.6C). Similar to the 
observations in LPS-treated Camp-/- BMDMs, CRAMP peptide treatment down-regulated 
LPS-induced Il-1β, Il-6 and Tnf-α mRNA expression in a dose-dependent manner (Figure 
2.6D). Importantly, the protein level of IL-1β in the LPS-treated RAW264.7 cell culture 





Figure 2.6 NLRP3 inflammasome activation and LPS-induced inflammatory 
cytokine expression in macrophages were attenuated by synthetic CRAMP peptide.  
(A) LPS-induced inflammatory cytokine expression in WT and Camp-/- BMDMs treated 
with CRAMP peptide. (B) IL-1β protein concentrations in the culture medium of 
BMDMs. (C) Immunoblotting of NLRP3 inflammasome complex proteins and 
quantification in mouse macrophage RAW264.7 cells. (D) LPS-induced inflammatory 
cytokine mRNA expression in RAW264.7 cells treated by CRAMP peptide. (E) IL-1β 
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protein levels in the cultural media of RAW264.7 cells. Data are expressed as mean ± 
SEM (n=3). Columns with different letters are significantly different. 
 
2.3.7 CRAMP Deficiency Exacerbated Alcohol-induced Endogenous Danger Signals 
Whether CRAMP is involved in the Signal 2 regulation in NLRP3-inflammasome 
is not clear. ATP and uric acid (UA) have been identified as endogenous danger signals 
for NLRP3 inflammasome activation in ALD 114,115. The serum concentration of ATP and 
UA in Camp-/- mice and their WT controls were measured. Results showed that mice 
lacking CRAMP had higher serum concentrations of UA and ATP (Figure 2.7A) 
compared to their WT controls. Importantly, analysis of the banked serum samples from 
alcohol use disorder (AUD) patients revealed a significant positive correlation between 
serum IL-1β and UA concentrations in AUD patients with ALD, but only an insignificant 
inverse association was observed in AUD patients without ALD (Figure 2.7B). Next, we 
examined whether treatment with CRAMP peptide can suppress UA-exacerbated IL-1β 
production in LPS-primed RAW264.7 macrophages. To exclude the effects of CRAMP 
peptide on LPS binding, cells were washed with PBS after LPS treatment and 
immediately exposed to UA and CRAMP in FBS-free media. UA alone had no effect on 
cellular pro-IL-1β and cleaved IL-1β protein levels, which were, however, increased by 
LPS treatment (Figure 2.7C). Addition of UA to LPS-primed cells showed no effect on 
cellular pro-IL1β and cleaved IL-1β (Figure 2.7C), but significantly increased media IL-
1β protein concentration (Figure 2.7D). Importantly, CRAMP peptide treatment 
completely inhibited cellular pro-IL-1β, cleaved IL-1β expression and the mature IL-1β 
concentration in culture media (Figure 2.7C&D). In contrast to RAW264.7 cells, the 
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addition of UA to LPS-primed BMDMs dramatically increased cellular cleaved IL-1β 
expression in both WT and Camp-/- mice, which were significantly reduced by CRAMP 
peptide. Of note, LPS-primed Camp-/- BMDMs showed increased levels of Caspase-1 
p12 and pro IL-1β protein level compared to control BMDMs, along with slightly 
increased levels of cellular cleaved IL-1β (Figure 2.7E). A similar inhibitory effect of 
CRAMP peptide on mature IL-1β production in RAW264.7 culture media was observed 
in BMDMs; however, no differences were found between WT and Camp-/- mice (Figure 
2.7F). These results suggested that CRAMP deficiency causes UA dysregulation in ALD 










Figure 2.7 Deficiency of CRAMP exacerbated the alcohol-induced endogenous 
danger signal, uric acid (UA), which correlates with the upregulated IL-1β 
production.   
52 
 
(A) Serum UA and ATP level. Data are expressed as mean ± SEM, (n≥8). *p<0.05, 
**p<0.01. (B) UA was inversely and insignificantly associated with IL-1β in alcohol use 
disorder (AUD) patients without ALD (left panel); UA was positively and significantly 
associated with IL-1β in AUD patients with mild ALD (right panel). Data are expressed 
as mean ± SEM, (n≥15). (C) Immunoblotting (left panel) and quantification (right panel) 
for Caspase-1 and IL-1β protein in LPS and UA treated RAW264.7 cells. LPS: 500 
ng/ml; UA (Uric acid): 500uM. CRAMP peptide: 10 µg/ml. (D) IL-1β protein level in 
RAW264.7 culture medium. (E) Immunoblotting of BMDM lysates from WT and Camp-
/- mice. (F) IL-1β protein level in BMDM culture medium. Data are expressed as mean ± 
SEM, (n≥4). Columns with different letters are significantly different. 
 
2.3.8 CRAMP Deficiency Exacerbated Alcohol-induced Oxidative Stress 
Alcohol metabolism-generated reactive oxygen species is a hallmark in ALD 
development and progression 116. UA metabolism is regulated by xanthine oxidase (XO), 
an important enzyme essential for the endogenous production of UA as a final product of 
purine metabolism. XO activation is upregulated by oxidants, which, in turn, produces 
more reactive oxygen species (ROS) 117. XO activity was increased significantly in the 
livers of Camp-/- mice fed alcohol ((Figure 2.8A). Immunoblots showed increased 
CYP2E1 in the livers of alcohol-fed Camp-/- mice compared to WT mice, although it was 
not statistically significant (Figure 2.8B). Camp-/- mice had increased DHE staining under 
control conditions, and alcohol feeding significantly increased hepatic superoxide and 
hydrogen oxide species, which were markedly elevated in Camp-/- mice fed alcohol 
(Figure 2.8C). These observations were then confirmed in an in vitro study using the 
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mouse hepatocyte cell line, Hepa1-6. Knockdown of CRAMP in Hepa1-6 cells was 
achieved by transfecting cells with CRAMP specific siRNA (siRNA-Camp), while the 
control cells were transfected with non-targeting siRNA (siRNA-NT). Desferrioxamine 
(DFO), a Hif-1α activator, was used as an inducer for Camp expression in Hepa1-6 cells. 
DFO is an iron-chelator that induces hypoxic conditions and, thus, increases Hif-1α 
activation, which is positively correlated with CAMP expression in ALD patients (Figure 
2.1F). As expected, DFO induced a significant increase of Camp expression in Hepa1-6 
cells transfected with siRNA-NT (Hepa-siR-NT) but not with siRNA-Camp (Hepa-siR-
Camp), confirming that CRAMP was efficiently knocked down (Figure 2.8D). 
Additionally, Hepa-siR-Camp cells had significantly higher mRNA levels of heme 
oxygenase (HO)-1 (gene name Hmox-1) than Hepa-siR-NT cells with or without DFO 
treatments (Figure 2.8D). These results indicated enhanced oxidative stress when 
CRAMP was lacking. Next, the expression of genes involved in oxidative stress was 
analyzed in transfected cells treated with ethanol. Ethanol significantly increased Hmox-
1, Nrf2, Gsr, Cat, Gstp1 and Gpx1 mRNA expression in Hepa-siR-Camp cells, while no 
differences were observed in Hepa-siR-NT cells by ethanol (Figure 2.8E). Importantly, 
UA concentration in culture supernatant was increased by alcohol exposure in cells 
lacking CRAMP, but there was no change in cells transfected with non-targeting siRNA 
(Figure 2.8F). Together, these results suggest that CRAMP deficiency causes exacerbated 
oxidative stress that partially contributes to the increased level of the danger signal, UA, 







Figure 2.8 Deficiency of CRAMP exacerbated alcohol-induced oxidative stress. 
(A) Xanthine oxidase (XO) activity was measured in the serum and liver lysates from 
alcohol-fed mice. (B) Immunoblotting (left panel) and quantification (right panel) for 
CYP2E1 protein in liver lysates. (C) Liver ROS production (left panel) and quantification 
(right panel) by DHE staining. Magnification: 100X. Data are expressed as mean ± SEM, 
(n≥8). *p<0.05, **p<0.01. (D) Validation of knockout efficiency by siRNA-Camp 
transfection in desferrioxamine (DFO) treated the mouse hepatocyte cell line, Hepa1-6 
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cells (left panel). DFO-induced oxidative stress in transfected Hepa1-6 cells (right panel). 
(E) Ethanol induced expression of genes involved in oxidative stress production in 
Hepa1-6 cells. Ethanol: 400mM, 4hours. (F) Ethanol induced-UA production in Hepa1-6 
culture supernatant (fold change). Data are expressed as mean ± SEM, (n≥4). *p<0.05, ** 
p<0.01. Columns with different letters are significantly different.  
 
2.3.9 CRAMP Peptide Administration Reversed Alcohol-induced Liver Steatosis and 
Injury  
Next, we examined whether administration of CRAMP peptide to Camp-/- and 
WT mice could attenuate alcohol-induced liver damage. Three days of synthetic CRAMP 
peptide administration (Figure 2.9A) marginally suppressed alcohol feeding-increased 
Saccharibacteria abundance and elevated Akkermansia abundance in Camp-/- mice, while 
no change was found for the total bacteria load in fecal samples (Figure 2.3D). CRAMP 
peptide treatment did not alter serum AST levels but did significantly reduce ALT levels 
in WT mice fed alcohol (Figure 2.9B). In Camp-/- mice, both AST and ALT levels were 
markedly decreased by CRAMP peptide (Figure 2.9B). CRAMP peptide administration 
robustly reduced alcohol-induced hepatic fat accumulation in both Camp-/- and WT mice 
(Figure 2.9C), and this was confirmed by hepatic triglyceride and free fatty acid contents 
(Figure 2.9D). CRAMP peptide treatment significantly reduced hepatic mRNA 
expression of Il-1β and Mcp-1 in WT and Camp-/- mice (Figure 2.9E). In contrast, anti-
inflammatory cytokine Il-10 expression was upregulated by CRAMP peptide in both 





Figure 2.9 CRAMP peptide administration rescued alcohol-induced liver steatosis 
and injury.  
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(A) Illustration of feeding and treatment timeline. (B) Serum transaminases AST and ALT. 
(C) Representative photomicrographs of liver sections of H&E (100x) and Oil Red O 
staining (200x). (D) Hepatic level of triglycerides and free fatty acids. (E) Hepatic mRNA 
expression of Il-1β, Mcp-1. (F) Hepatic mRNA expression of Il-10. Data are expressed as 
mean ± SEM, (n≥4). *p<0.05, **p<0.01, ***p<0.001.  
 
2.3.10 CRAMP Peptide Administration Attenuated Alcohol-induced IL-1β Production via 
Inhibiting Inflammasome Activation  
Serum IL-1β concentration was marginally decreased in the WT mice but robustly 
decreased in Camp-/- mice by CRAMP peptide (Figure 2.10A), indicating a reduced 
inflammasome activation. Serum LPS levels were not significantly altered by CRAMP 
peptide (Figure 2.10B), but Lbp and Cd14 mRNA expression was significantly reduced in 
both Camp-/- and WT mice by CRAMP peptide (Figure 2.10C). In addition, CRAMP 
peptide dramatically decreased serum UA levels and XO activity in Camp-/- mice but only 




Figure 2.10 CRAMP peptide administration attenuates alcohol-induced IL-1β 
production via inhibiting inflammasome activation signaling.  
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(A) Serum IL-1β protein levels. (B) Serum LPS levels. (C) Hepatic mRNA expression of 
Lbp, Cd14 and Tlr-4. (D) Serum UA levels. (E) Serum XO activity. (F) Model for the 
effects of CRAMP on ALD. Data are expressed as mean ± SEM, (n=4-8). 
 
2.4 Discussion 
Hepatic inflammation is a hallmark of ALD development. Alcohol exposure 
reduces antimicrobial peptide expression and causes intestinal bacterial dysbiosis, 
immune dysregulation and gut barrier dysfunction, which, in turn, leads to increased 
endotoxin release and hepatic bacterial translocation that activate TLR-4 on Kupffer cells 
and causes liver inflammation. In addition to LPS-induced TLR activation, recent studies 
demonstrate that endogenous danger molecules are critical in hepatic inflammasome 
activation in ALD development 114,115. Studies in this chapter showed that CRAMP plays 
a role in both LPS-mediated initiation and UA-mediated maturation of inflammasome 
activation in mice fed alcohol.  
Alcohol exposure induces gut dysbiosis, which is largely attributed to the reduced 
expression of antimicrobial factors. Reg3 lectins represent an important family of gut-
derived AMPs, and depleting Reg3b and Reg3g exacerbated, while increasing Reg3g 
expression attenuated, gut dysbiosis and alcohol-induced liver injury 76. A recent study 
further showed that alcohol feeding caused -defensin dysfunction, which was critically 
involved in the pathogenesis of AH in mice 78. CRAMP is the only member in the 
cathelicidin family of AMP, and it is transcriptionally regulated by vitamin D receptor 
and hypoxia-inducible factor 1 (HIF-1α). Our recent study demonstrated that intestinal 
HIF1 plays an important role in maintaining gut microbiota homeostasis and gut barrier 
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function by activating barrier-protecting factors, such as CRAMP, -defensins, cluster of 
differentiation 73 (CD73), and claudin-1. Depleting HIF-1α in the intestine exacerbated 
ALD in mice accompanied by a reduction of CRAMP, while activation of HIF-1α 
increased CRAMP and attenuated ALD 79. It was hypothesized that CRAMP may 
represent another important AMP in alcohol-induced gut dysbiosis in ALD. Indeed, 
alcohol exposure induced a significant decrease of Bacteroidetes and an increase of 
Firmicutes in Camp-/- mice compared to WT mice, as has been demonstrated in previous 
studies 53,106,107. Ferrere et al. showed that the decreased fecal Bacteroidetes/Firmicutes 
ratio occurred only in alcohol sensitive mice but not in resistant mice 107. It is thus 
possible that CRAMP deficiency contributes to the gut dysbiosis and sensitizes the mice 
to alcohol exposure, which leading to severe ALD. At the genus level, Akkermansia was 
decreased in Camp-/- mice. Although the role of Akkermansia in ALD remains elusive, it 
has been shown that Akkermansia abundance declined in both ALD patients and in mice 
fed chronic alcohol, and supplementation with Akkermansia showed a protective effect in 
ALD 118. Our data suggested a critical involvement of CRAMP in maintaining the 
homeostasis of gut microbiota by selectively inhibiting bacterial growth in ALD.  
Unlike Reg3, which is expressed mainly in the intestine, CRAMP is expressed in 
multiple organs, including intestine, lung, liver, spleen, and adipose tissue. Alcohol 
treatment increased hepatic but decreased intestinal CRAMP expression in mice. In 
contrast to intestinal HIF-1α 79, the role of hepatic HIF-1α in lipid metabolism in ALD is 
the subject of conflicting reports 119-121. It is known that alcohol exposure induces hepatic 
hypoxia 122 which then increases HIF-1α expression and upregulates a variety of genes, 
including CRAMP, that have either deleterious or protective roles. The induction of 
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hepatic Camp in ALD mice is likely a protective mechanism against alcohol-induced 
injury, since CRAMP deficiency exacerbated ALD. Agreeing with the study in mice, 
patients with ALD had higher hepatic CAMP mRNA expression.  
The depletion of CRAMP in mice fed alcohol led to an exacerbated ALD 
response accompanied by an increased hepatic inflammasome activation, which requires 
two signals. LPS activation of TLR4 initiates the Signal one in inflammasome activation, 
and endogenous, sterile, molecules are required to activate Caspase-1 to produce mature 
IL-1β, which kills hepatocytes. Interestingly, although Camp-/- mice had dysbiosis in 
response to alcohol exposure, serum LPS levels were not altered, indicating that CRAMP 
deficiency-exacerbated ALD is likely independent of gut barrier function. Instead, 
hepatic mRNA expression of LBP and CD14 were significantly increased in Camp-/- 
mice. LBP is an acute phase protein that presents LPS to surface pattern recognition 
receptors, such as CD14 and TLR4, to elicit immune responses 123. Increased LBP and 
CD14 in Camp-/- mice suggest a functional increase of LPS by increasing LPS binding to 
its activation complex. Indeed, CRAMP peptide inhibited LPS binding to macrophages in 
a dose-dependent manner. These results demonstrate that increased CRAMP in the liver 
in response to alcohol might serve as an inhibitory mechanism for LPS signaling.  
One of the most important finding of this study was the significantly elevated 
serum IL-1β protein and hepatic Nlrp3 and Caspase 1 mRNA expression in Camp-/- mice. 
This indicated an activation of the Signal 2 in alcohol-induced inflammasome activation. 
Previous research demonstrated that UA or ATP, as Signal 2 molecules, play a causal 
role in the liver inflammation caused by acetaminophen, ischemia-reperfusion injury and 
alcohol 114. Agreeing with these studies, we showed that serum IL-1β levels are positively 
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correlated with levels of UA in patients with ALD, and UA combined with LPS induced 
a robust elevation of mature IL-1β levels, further demonstrating the requirement of 2 
signals in IL-1β production. Most importantly, mice lacking CRAMP that were fed 
alcohol had an elevation of serum UA levels, and CRAMP peptide treatment lowered the 
UA concentration and blocked the IL-1β elevation. UA metabolism is regulated by 
multiple mechanisms. Our data suggest that the elevation of UA in Camp-/- mice fed 
alcohol is likely attributed to the increased XO activity resulting, at least in part, from 
alcohol-induced oxidative stress. Taken together, our data suggest that CRAMP inhibits 
inflammasome activation by decreasing UA production in mice with experimental ALD. 
There are intrinsic mechanisms that can control alcohol-induced liver inflammation. 
Alcohol-increased hepatic CRAMP expression is likely an adaptive response to inhibit 
both LPS activation and UA-mediated Signal 2 activation in alcohol-induced 
inflammasome activation.  
The presented data demonstrated that exogenous CRAMP administration reduces 
alcohol-induced hepatic steatosis, which is in line with previous research showing that 
lentivirus-mediated CRAMP overexpression reduced hepatic fat accumulation in obese 
subjects 88. Which was further demonstrated is that CRAMP peptide reduces alcohol-
induced LPS and inflammasome activation by decreasing hepatic Lbp and Cd14 
expression and UA production. These findings suggest that CRAMP may represent a 
novel drug target for treating fatty liver and liver diseases related to hepatic 
inflammation. 
In summary, the studies in this chapter identified the protective role of LL-
37/CRAMP in alcohol-induced liver inflammation, steatosis and injury by maintaining 
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gut microbiota homeostasis and by attenuation of inflammasome activation via inhibiting 
LPS activation and UA production (Figure 2.10F). The knowledge gained from the 
present study advances the understanding of the role of CRAMP in alcohol-induced liver 




CHAPTER 3 HIGH FAT FEEDING PRIMES THE LIVER TO ALCOHOL-INDUCED 





3.1.1 The Synergistic Effects of Obesity and Alcohol 
Being overweight or obese has long been recognized as one of the most common 
comorbidities of alcohol-associated liver disease (ALD), and it can have significant 
effects on the initiation and progression of the disease. As early in 1988, researchers had 
already associated increased body weight (BW) with liver damage in asymptomatic 
alcoholic patients, suggesting that overweight is a risk factor for ALD 124. The interaction 
of excessive alcohol drinking and obesity has been further confirmed in many more 
comprehensive clinical studies, whose subjects included obese alcoholics, non-obese 
alcoholics and obese non-alcoholics as controls. Higher serum ALT levels were often 
found in obese alcoholics, and this group of alcoholic subjects usually has a higher risk of 
progressing from fatty liver (simple steatosis) to advanced forms of ALD, such as 
steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma 36-43.  
The detrimental co-effects of alcohol exposure and diet-induced obesity and 
genetic obesity were explored in studies using rodent models which have revealed 
underlying mechanisms on how alcohol and obesity work synergistically or additively to 
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promote development/progression of ALD 45,125-132. Rats fed a choline-deficient (CD) diet 
and gavaged with commercial whiskey three times per week, including a final binge, for 
three months had increased liver injury, hepatic steatosis, apoptotic cell death and fibrosis 
132.  Tsukamato et al. demonstrated early in 1986 that the combination of high fat diet and 
ethanol can induce liver fibrosis in rats 127. A recent study by Dr. Bin Gao’s group further 
elucidated the underlying mechanism that the neutrophils and hepatic stellate cells 
interact to promote fibrosis in experimental steatohepatitis in mice 129. Oxidative stress 
and nitrosative damage were linked to the synergistic effects of obesity and alcohol 
consumption in rodents. Feeding rats a HFD for one month followed by gavage with 
ethanol every 12 h for the last three days increased hepatic oxidative stress but did not 
increase serum ALT levels 125.  
In genetically obese fa/fa Zucker rats, a binge (gavage) of ethanol every 12 h for 
three days increased liver injury, steatosis and inflammation when compared to their lean 
littermates 131. More mechanistic studies were conducted with genetically obese mice 
(ob/ob). Moderate ethanol binges induced significant liver damage (hepatocyte apoptosis) 
in ob/ob mice by increasing TNF-α and decreasing nuclear NF-κB activity, which 
unleashed the apoptotic effects of TNF- α 130. Exacerbated hepatic steatosis and injury 
were seen in a chronic ethanol feeding model with ob/ob mice, and the mechanisms is 
thought to be the impairment of hepatic lipid metabolism mediated by the SIRT1-AMPK 
signaling pathway 126.  
Xu et al., using an ASH mouse model, described nitrosative stress mediated by 
M1 macrophage activation, adiponectin resistance, and accentuated ER and 
mitochondrial stress as underlying potential mechanisms for synergistic steatohepatitis 
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caused by moderate obesity and alcohol. In this study, moderate obesity was induced by 
intragastrically overfeeding of high fat diet, followed with continuous intragastric 
infusion of alcohol 128. Another important mechanism by which HFD-plus-binge ethanol 
synergistically exacerbate liver injury is through the induction of chemokines and 
subsequent hepatic neutrophil infiltration. In another experimental alcoholic 
steatohepatitis (ASH) model that mimics acute ASH in obese binge drinkers, Change et 
al. showed that feeding mice with short- or long-term HFD plus a single ethanol binge 
synergistically increased the serum and hepatic free fatty acids, chemokine CXCL-1 
expression and exaggerated neutrophil infiltration in the liver, eventually producing 
severe liver injury 45. 
 
3.1.2 Neutrophils and the Innate Immune Response in ALD 
Inflammation is a hallmark of ALD and NAFLD/NASH, and has been recognized 
as a host defense reaction caused by infection or tissue damage in different disease 
models 67,69,133-135. This host defense is aimed at eliminating the inflammatory stimulus 
and protecting the surrounding tissue from further damage, thus making it necessary for 
the survival of the host. Neutrophils are the most abundant leukocytes in circulation and 
play a critical role in innate immune response. Upon tissue injury, neutrophils are largely 
increased in number and are recruited to the damaged or infected site. Neutrophils are the 
first cells to be recruited to sites of damage or infection where they promote innate 
immunity through phagocytosis, release of antimicrobial products and production of 
signals that recruit or activate other immune cells 136. The inflammatory response 
represents a prominent example of cell dispersal and clustering that must be tightly 
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controlled; in another word, a deficient or excessive production of neutrophils in response 
to damage or infection could also be detrimental or beneficial at the same time 137. In 
bacterial infectious respiratory disease models, selective depletion of the neutrophil cell 
population results in profound defects in the clearance of bacteria from the lungs, and the 
repletion of neutrophils in neutropenic mice restores the host defense 138. On the other 
hand, excessive neutrophil presence can be injurious, as it may perpetuate inflammation 
and cause collateral tissue damage through neutrophil-released enzymes or radicals 136.  
Clinical studies of AH patients have demonstrated that hepatic expression of 
several major CXC chemokines, such as Cxcl-1/Gro-α, Il-8, Cxcl-5, and Cxcl-6,  was 
upregulated and is correlated with neutrophil infiltration and disease severity 139. Similar 
observations were found in obese patients with nonalcoholic steatohepatitis (NASH) that 
hepatic expression of Cxcl-1 and Il-8 was increased, accompanied by the accordingly 
upregulated chemokine receptors for Cxcl-1 and Il-8 140. In this study, hepatic expression 
of 58 of 222 inflammatory and immune response genes was upregulated in NASH 
patients, particularly the genes encoding chemokines and chemokine receptors involved 
in leukocyte recruitment.  
In a high fat diet plus ethanol (HFD+E) model, binge alcohol gavage may act as a 
second hit to induce a more profound increase of neutrophil infiltration in a HFD-primed 
liver, exacerbating liver damage. Neutrophil infiltration has been implicated in promoting 
liver damage in various types of liver diseases 141 including drug-induced liver injury 142-
145 and alcoholic liver injury 146,147. The mechanisms of how the trafficking of neutrophils 
is regulated under physiologic and pathologic conditions have been explored 148. 
Neutrophil infiltration is mediated by multiple adhesion molecules, chemokines and 
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cytokines, or the so-called classic chemoattractant 149. Several factors are endothelium-
expressed molecules, such as E-selectin, P-selectin, vascular cell adhesion molecule 1 
(VCAM-1) and intercellular adhesion molecule1 (ICAM-1). Neutrophil-expressed 
proteins also participate is this process, such as L-selectin (CD62L), E-selectin ligand 1 
(ESL-1), P-selectin glycoprotein ligand 1 (PSGL-1), CD44, and members of the CXC 
chemokine family including chemokine (C-X-C motif) ligand-1 (CXCL-1), CXCL-2 and 
CXCL-8 (IL-8) 137,150. IL-8/CXCL-8 was the first identified chemokine early in 1987 151. 
This has led to the cloning of several chemokine receptors, including CXCR-1 and 
CXCR-2. CXCR-1 is highly selective for IL-8/CXCL-8, whereas CXCR-2 is responsive 
to IL-8 and other CXC chemokines. CXCR-2 is a G protein coupled chemokine receptor 
expressed on neutrophils 137,152. In mice, CXCR-2 and another chemokine receptor, 
CXCR-4, play major roles in regulating neutrophil trafficking. High CXCR-4 expression 
retains immature neutrophils in the bone marrow while high CXCR-2 expression allows 
the mobilization of mature neutrophils in the blood and their subsequent recruitment to 
inflamed sites in response to transient CXCR-4 inhibition 153.  
CXCL-1 and CXCL-2 are the two most studied ligands of CXCR-2 and are potent 
neutrophil chemoattractants required for the mature neutrophils trafficking 139,152,154-157. A 
recent study revealed a critical role of CXCL-1 in HFD and alcohol consumption-induced 
liver injury and inflammation. Chang et al. analyzed the hepatic expression of an array of 
adhesion molecules, chemokine and cytokines using a mouse HFD+E model, and found 
that Cxcl-1 increased up to 20-fold and 30-fold in the liver after 3 days of HFD and 3 
months of HFD+E feeding, respectively 45. This is consistent with clinical observations 
that hepatic Cxcl-1 markedly increased in AH patients, and is positively correlated with 
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hepatic neutrophil infiltration 139. The authors showed that HFD increases free fatty acids 
(FFAs) in the liver and serum and up-regulates hepatic CXCL-1 expression, resulting in 
an exaggerated neutrophil infiltration in the liver and eventually exacerbated liver injury 
45.  
 
3.1.3 Cathelicidins: Chemoattractants for Neutrophil Infiltration 
Other molecules have also been identified to bind CXCR2 in terms of initiating 
and directing neutrophil infiltration. The human AMP cathelicidin, LL-37, has been 
described as a chemoattractant 92,93 and may act as a functional ligand for CXCR2 on 
human neutrophils. Zhang et al. demonstrated that LL-37 was shown to function similarly 
to the CXCR-2-specific chemokine, CXCL-1, in terms of receptor down-regulation and 
intracellular calcium mobilization on freshly isolated neutrophils. IL-8/CXCL-8 is a 
chemokine that binds both CXCR-1 and CXCR-2; when neutrophils were pretreated with 
IL-8/CXCL-8, the calcium mobilization was completely blocked in neutrophils in 
response to LL-37. Similar inhibitory effects accompanied by the subsequent blockade of 
neutrophils migration were observed in neutrophils treated with a selective CXCR2 
antagonist. Moreover, CXCR2, but not CXCR1, was internalized in LL-37-treated 
neutrophils, further confirming the specificity of LL-37 as a functional ligand for CXCR2 
158.  
Cathelicidins, defensins and REG3 lectins are 3 major AMP families that have 
been extensively studied in different disease models, including metabolic diseases such as 
ALD 76,78,159. The cathelicidin family is composed a number of multifunctional cationic 
AMPs which are also known as host-defense peptides (CHDP) 160. LL-37 is the only 
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human cathelicidin that has been identified, and it has a murine ortholog named CRAMP 
(Cathelicidin-related antimicrobial peptide). In addition to microbicidal potential 161-163, 
LL-37/CRAMP also showed capacity to modulate inflammation and immunity 87,164-167. 
Sun et al. demonstrated that pancreas-produced CRAMP plays a crucial role in T cell 
function in autoimmune diabetes, and the expression of CRAMP is regulated by gut 
microbiota 87. In addition to CXCR-2, LL-37/CRAMP has also been reported to exert 
chemotactic functions through other membrane receptors, such as formyl peptide 
receptor-like 1/2 in mice (FPR1/FPR2). De et al. reported that LL-37 is chemotactic for 
human monocytes and FPR1-transfected human embryonic kidney 293 cells. LL-37 can 
induce Ca2+ mobilization in monocytes, and this can be cross-desensitized by an FPR1-
specific agonist. Moreover, this group showed that LL-37 utilizes FPR1 as a receptor to 
chemoattract human neutrophils and T lymphocytes, which are known to express FPR1 
93. Kurosaka et al. showed later on that the mouse canthelicidin, CRAMP, just as LL-37, 
is also chemotactic for human monocytes, neutrophils, macrophages and mouse 
peripheral blood leukocytes through FPR2. Importantly, an injection of CRAMP into 
mouse ear punches resulted in the recruitment of neutrophils and monocytes, providing in 
vivo evidence that CRAMP acts as a chemoattractant factor. Moreover, the simultaneous 
administration of CRAMP and ovalbumin as an experimental antigen to mice, promoted 
both humoral and cellular immune responses in mice, suggesting that CRAMP also acts 
as an alarmin in response to danger signals and contributes to both innate and adaptive 
immunity of the host 168.  
Another proposed receptor for LL-37/CRAMP is P2X purinoceptor 7 (P2X7). 
P2X7 receptor is a trimeric ATP-gated cation channel found predominantly on immune 
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cells. The activation of P2X7 results in the release of proinflammatory mediators and cell 
proliferation and death. A recent study demonstrated that LL-37 is internalized by human 
macrophages, and this is a time-, dose-, temperature-, and peptide sequence-dependent 
endocytotic process through P2X7. In macrophages pretreated with P2X7 antagonists, 
significantly less internalized LL-37 was detected. The internalized LL-37 was further 
shown to traffic to endosomes and lysosomes and contribute to intracellular clearance of 
bacteria by human macrophages, which synchronized with increased reactive oxygen 
species and lysosome formation. Importantly, the researchers showed that human 
macrophages have the potential to import LL-37 released from activated human 
neutrophils 169. The interaction between P2X7 receptors and cathelicidins has been 
reported to be species-specific, in some cases (human) positive while in others (mouse) 
negative 170,171.  
CXCR-2 has been found to be the most specific receptor for LL-37/CRAMP to 
stimulate the immune responses in neutrophils. Although FPR2 and P2X7 have been 
recognized as LL-37/CRAMP receptors in neutrophils, macrophage and monocytes, a 
study analyzed 21 neutrophils receptors showed that only CXCR-2 was down-regulated 
by LL-37. Furthermore, a CXCR-2 inhibitor, SB225002, inhibited LL-37-stimulated 
migration of monocytes, while a FPR2 ligand, peptide WKYMVm, failed to do so 158. 
This highlights the critical role of cathelicidins as chemoattractant in neutrophils 
infiltration.  
The previous studies showed that CRAMP deficiency exacerbated binge-on-
chronic alcohol-induced liver injury, and this is through the regulation of gut microbiota 
composition and the inhibition of inflammasome activation via inhibiting LPS delivery to 
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the macrophages and inhibiting uric acid production and signaling. In this chapter, it was 
aimed to investigate the role of CRAMP as chemoattractant in alcohol-induced liver 
injury in HFD-fed mice, and to explore the underlying mechanism(s).  
 
3.2 Materials and Methods  
3.2.1 Animals  
CRAMP KO (Camp-/-) male mice (Jackson Laboratory, Bar Harbor, ME) aged 8-
10 weeks were used with their age-matched littermates WT mice. Mice were maintained 
at 22 °C with a 12 h light/dark cycle and had free access to a normal chow diet and tap 
water. WT and Camp-/- mice were subjected to adjusted calories control diet (CD) (10% 
total kcal from fat) or adjusted calories high fat diet (HFD) (42% total kcal from fat) or 
feeding for 10 weeks, followed by one binge alcohol gavage for the alcohol group (HFD 
+E) or maltose dextrin gavage in substitution of ethanol for the control group (CD / 
HFD). Timelines of experiments and mouse chow composition are depicted in Figure 3.1. 
During the 10-week feeding period, body weight and food consumption in each feeding 
group were recorded weekly. At the end of the 6th and 10th week, an oral glucose 
tolerance test (OGTT) was conducted in each CD or HFD feeding group. At the time of 
harvest, a portion of the liver (left lateral liver lobe) and spleen tissue were collected in 
ice-cold DMEM cell culture medium which was supplemented with 2% FBS (fetal 
bovine serum) immediately after opening of the abdominal cavity for flow cytometry 
analysis. The serum and the tissues of the liver, spleen, intestine, epidydimal white 
adipose tissue (eWAT), and fecal samples and cecum contents were collected.  
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3.2.2 ALT and AST Measurements   
Serum activity levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were determined using standard kits (Thermo Scientific, 
Waltham, MA) following the manufacturer’s instructions. 
 
3.2.3 Histological Analysis  
Liver tissue and epidydimal white adipose tissue (eWAT) were collected and 
fixed in 4% paraformaldehyde and embedded in paraffin. The paraffin-embedded liver 
tissue blocks were then sliced at 5 µm thickness and eWAT tissue sliced at 6 µm on a 
microtome. The sliced tissues were then floated in a water bath containing distilled water 
at 45°C for the liver tissue and at 40°C for the adipose tissue. Sections were then 
transferred onto glass slides. Slides were air dried for 2 days or dried in a 37°C incubator 
overnight before the day of staining. Otherwise, they were stored at room temperature for 
future use. Slides were deparaffinized with Citrisolv (Decon, King of Prussia, PA) and 
rehydrated by immersing in graded ethanol solutions before staining.  
H&E Staining Hematoxylin and eosin (H&E) were used to stain the nuclear and 
cytoplasm components, respectively. After staining, sections were then dehydrated 
through graded alcohol, cleared in Citrisolv and then mounted with Cytoseal Xyl 
(Thermo Scientific, Waltham, MA) and observed by microscopy.  
CAE Staining Infiltration of neutrophils in the liver was assessed by chloroacetate 
esterase (CAE) staining according to manufacturer’s instructions (Naphthol AS-d 
Chloroacetate Kit, Sigma, St. Louis, MO). Briefly, liver sections were incubated in a 
solution of naphthol AS-D chloroacetate, the naphthol AS-D chloroacetate is 
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enzymatically hydrolyzed by a “specific esterase” in neutrophils, liberating a free 
naphthol compound. This then couples with a diazonium compound, forming highly 
colored deposits at sites of enzyme activity that can be visualized under microscopy. 
Numbers and areas of neutrophil clusters were quantified as previously described 172.  
Ly6G & CRAMP co-localization Staining Following deparaffinization, antigen 
retrieval was performed on slides in 10mM citrate buffer (pH 6.0) for 20 min at 95ºC. 
Blocking buffer containing 10% fetal bovine serum (FBS) in PBS (Sigma, St. Louis, 
MO) was added onto the slides and the slides were incubated in a humidified chamber at 
room temperature for 1 hour, for the blocking of non-specific antibody binding. Sections 
were then incubated with primary antibody Ly6G (rat-anti-mouse), Cathelicidin (mouse 
CRAMP, rabbit-anti-mouse) (Abcam, Cambridge, UK) at a concentration of 1:200 in 
10% FBS and incubated in a humidified chamber overnight at 4°C. On the next day, 
slides were washed with PBS three times, 1 minute/time before being incubated with 
AlexaFluor-conjugated secondary antibodies (Life technologies, Carlsbad, CA). 
AlexaFluor 488 (Green) (donkey-anti-rat) and AlexaFluor 594 (Red) (goat-anti-rabbit) at 
a concentration of 1:200 in 10% FBS were used to incubate the slides for 1.5 hours. 
DAPI (Invitrogen, Carlsbad, CA) was used for nuclei counterstaining. The fluorescence 
was examined under confocal microscopy and the intensity of fluorescence was 
quantified using Image J. 
 
3.2.4 Lipid Accumulation 
Liver tissues were homogenized in 50mM NaCl (Sigma, St. Louis, MO) solution 
in distilled water. The homogenates were then used for lipid extraction using methanol 
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(Fisher chemical, Fair Lawn, NJ) and chloroform (Fisher chemical, Fair Lawn, NJ). Liver 
triglycerides (TG) and free fatty acid (FFA) levels were determined using commercial 
kits according to the manufacturer’s instructions. (Thermo Scientific, Waltham, MA).  
 
3.2.5 RNA Isolation and Real-time RT-PCR 
The mRNA levels were assessed by real-time polymerase chain reaction (PCR). 
In brief, the total RNA was extracted from the liver and spleen tissue with Trizol reagent 
according to the manufacturer’s protocol (Life technologies, Carlsbad, CA) and reverse-
transcribed using cDNA supermix (QuantaBio, Beverly, MA). Quantitative real-time 
PCR was performed on an ABI 7500 real-time PCR thermocycler, whereas SYBR green 
PCR Master Mix (Applied Biosystems, Foster City, CA) was used for real-time PCR 
analysis. The relative quantities of target transcripts were calculated from duplicate 
samples after normalization of the data against the housekeeping gene, 18S (mouse). 
Relative mRNA expression was calculated using the Ct method. The primer pairs used 
were listed in Table Primers list.  
 
3.2.6 Immunoblots 
 Liver and spleen tissues were lysed in radioimmunoprecipitation assay (RIPA) 
buffer (Thermo Scientific, Waltham, MA). Lysed samples were then centrifuged for 15 
min at 12000 x g at 4°C, and the supernatants were collected. The protein concentration 
was measured by using a bicinchoninic acid assay (BCA) assay kit (Pierce, Thermo 
Scientific, Waltham, MA). Sample aliquots were boiled for 5 min and equal protein 
amounts (usually 35-50 μg) were separated by SDS-PAGE. Proteins were then 
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transferred to a nitrocellulose membrane. Blots were blocked for 1 h in Tris-buffered 
saline/Tween 20 (TBST buffer) (10 mM Tris–HCl, pH 8.0, 150 mM NaCl, and 0.05% 
Tween 20) containing 5% nonfat dry milk and incubated overnight at 4 °C with the 
different primary antibodies diluted (typically 1:1000; β-actin at 1:10000) in TBST buffer 
containing 3% BSA. Blots were then incubated in horseradish peroxidase (HRP)-
conjugated secondary antibodies (typically 1:5000 dilution) for 1 h at room temperature. 
Following treatment with supersignal west HRP substrate (MilliporeSigma, Billerica, 
MA), protein bands were detected by a ChemiDoc Molecular Imager (Bio-Rad, Hercules, 
CA). Quantification for the bands was performed using Image J software (National 
Institutes of Health) and normalized to β-actin. The following primary antibodies were 
used: CRAMP (Abcam, Cambridge, UK) and β-actin (Cell signaling, Danvers, MA). 
 
3.2.7 Serum CRAMP and CXCL-1 ELISA  
Mouse serum CRAMP protein levels were determined using mouse Cathelicidin 
ELISA kit (MyBiosource, San Diego, CA) and serum CXCL-1 levels in murine serum 
were determined using CXCL-1 ELISA kit (R&D, Minneapolis, MN) according to the 
manufacturers’ instructions, respectively.  
 
3.2.8 Flow Cytometry 
Hepatic leukocytes preparation: Hepatic leukocytes were prepared as previously 
described 173. Briefly, a portion of the liver tissue was collected immediately upon harvest 
and was homogenized with a 70-μm pore filter in complete DMEM with 2% FBS on ice. 
The homogenates were then centrifuged at 2300 rpm for 15 mins. After several washes, 
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the homogenates were resuspended in a 33% Percoll gradient at 22°C and centrifuged at 
2300 rpm for 20 min. The supernatant with the upper layer which contains the dead 
hepatocytes was discarded, and the cell pellet was collected. Red blood cells (RBCs) 
were then removed using red cell lysis buffer followed by a wash with 1xPBS and 
centrifugation.  
Flow cytometry analysis: Isolated hepatic leukocytes were blocked by incubating 
with CD32 antibody, then labeled with antibodies using standard procedures, as described 
previously 174. Gr-1, CD11b, Ly6C and F4/80 antibodies that are conjugated with PerCP, 
APC, FITC and PE from eBioscience (San Diego, CA) were used. Cells were analyzed 
by flow cytometry (FACSCanto, BD, Franklin Lakes, NJ). Analysis was performed using 
FlowJo Software (Tree Star, Ashland, OR).  
 
3.2.9 Oral Glucose Tolerance Test (OGTT)  
At week 6 and week 10, OGTT were performed for both CD and HFD fed WT 
and Camp-/-mice. Methods used are as previously described 175. Briefly, mice were fasted 
overnight for about 16 hours and weighed to calculate the glucose dose at 2.5 g/kg body 
weight. The working glucose solution was prepared at a concentration of 250 mg/ml in 
advance. Blood glucose levels of each mouse were determined by glucometer in tail vein 
blood before the glucose gavage (T0) and at 15 (T15), 30 (T30), 60 (T60) and 120 (T120) 
minutes following. Tail snipping is used to get blood. Before snips, the tail end was 




3.3 Statistics  
Statistical analyses were performed using the statistical computer package, 
GraphPad Prism version 6, (GraphPad Software Inc., San Diego, CA, USA), MS Excel 
2016 (Microsoft Corp., Redmond, WA) or SPSS 26.0 (IBM, Chicago, IL). Results are 
expressed as means ± standard error of the mean (SEM). Statistical comparisons were 
made using two-way analysis of variance (ANOVA) with Tukey’s post hoc test or 
Student’s t-test, where appropriate. Differences were considered to be significant at 
p<0.05. Columns with different letters are significantly different, or significance may be 
noted as *p<0.05, **p<0.01, ***p<0.001 between groups.  
 
3.4 Results 
3.4.1 Body Weight Change & Adipocyte Enlargement by HFD+E Treatment  
Ten-weeks of HFD feeding (Figure 3.1A & B) markedly increased the body 
weight of both WT and Camp-/- mice over time compared to those animals pair fed with a 
control diet (CD). However, the increase of body weight was more pronounced in WT 
mice (127.7% by CD vs 183.2 % by HFD) compared to Camp-/- mice (111.7 % by CD vs 
152.7 % by HFD). Importantly, Camp-/- mice grew much slower overall compared to WT 
mice, in both control diet and high fat diet feeding groups (Figure 3.2A). By monitoring 
the daily food intake in absolute amount (g) and caloric amount (Kcal), we found that 
WT mice, but not Camp-/- mice, fed HFD consumed much more food compared to those 
fed a control diet. Overall, Camp-/- mice consumed much less food than WT mice (Figure 
3.2B). The differences in body fat mass were then evaluated by determining the ratio of 
epididymal adipose tissue weight (eWAT) to body weight. The combination of HFD 
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feeding and binge ethanol gavage (HFD+E) significantly increased the absolute weight of 
eWAT and the ratio of eWAT/body in both WT and Camp-/- mice. No difference was 
found in the eWAT/body ratio between WT and Camp-/- mice. However, the absolute 
weight of eWAT was significantly lower in Camp-/- mice fed with either CD+E or HFD+E 
(Figure 3.2C). Histological analysis of the adipose tissue showed increased adipocyte size 
in both WT and Camp-/- mice by HFD+E feeding, with more pronounced adipocyte 
enlargement in WT mice (Figure 3.2D). These results indicated that CRAMP deficiency 
reduced body weight gain, adipose tissue weight and adipocyte enlargement in mice fed 
with high fat diet and binge ethanol gavage.  
 
Figure 3.1 Timelines of experiments & mouse chow composition.  
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(A) Schematic illustration of experimental design: mouse strain, feeding type and 
duration, measurements during the feeding period. OGTT: oral glucose tolerance test. (B) 





Figure 3.2 Body weight change & adipocyte enlargement by HFD+E treatment. 
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(A) Body weight change in percentage (left panel) and in absolute amount (right panel) 
from the start of feeding period. (B) Food consumption per mouse per day as in absolute 
amount (left panel) and as in Kcal (right panel). (C) eWAT weight to body weight ratio 
(left panel) and the absolute amount (right panel). (D) H&E staining of paraffin-
embedded eWAT tissue (left panel) and quantified adipocyte size (right panel). 
Magnification: 100X. Data are expressed as mean ± SEM, (n≥5). *p<0.05, **p<0.01, 
***p<0.001.  
 
3.4.2 The Effects of CRAMP Deficiency on Fasting Glucose Concentration and Glucose 
Intolerance 
To determine whether CRAMP deficiency affects glucose homeostasis, oral 
glucose tolerance tests (OGTT) were performed at week 6 and week 10. Fasting glucose 
concentrations were not significantly different between CD and HFD-fed WT mice at 
week 6. However, HFD feeding significantly increased fasting serum glucose level in 
Camp-/- mice, compared to their CD feeding controls and HFD feeding WT controls 
(Figure 3.3A). HFD itself did not increase glucose intolerance at week 6 in either WT or 
Camp-/- mice. Surprisingly, Camp-/- mice showed increased glucose intolerance compared 
to their WT controls, and this was independent of the CD or HFD feeding (Figure 3.3B). 
The fasting serum glucose level in WT mice fed HFD significantly increased by week 10, 
while HFD-fed Camp-/- mice had comparable fasting glucose levels to that of week 6 
(Figure 3.3 B,C). OGTT revealed that glucose tolerance was substantially decreased by 
HFD feeding in WT but not Camp-/- mice at week 10 (Figure 3.3D). These results 
indicated that HFD feeding increased fasting glucose concentrations in Camp-/- mice at 
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early stage but improved tolerance at a late stage. In contrast, HFD increased fasting 
glucose level and reduced glucose tolerance in WT mice over time.  
 
Figure 3.3 The effects of CRAMP deficiency on fasting glucose concentration and 
glucose intolerance.  
Fasting serum glucose of CD+E/HFD+E fed WT and Camp-/- mice at week 6 (A) and 
week 10 (C). Oral glucose tolerance test (OGTT) at week 6 (B) and week 10 (D). Blood 
glucose level before (time 0) and 15, 30, 60, 120 mins after glucose gavage were shown. 
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The lower panel showing the quantification of area under curve (AUC) of OGTT at week 
6 (left panel) and week 10 (right panel). Data are expressed as mean ± SEM, (n≥5). 
*p<0.05, **p<0.01, ***p<0.001. 
 
3.4.3 Alcohol Induced Less Liver Injury and Fat Accumulation in HFD-fed Camp-/- Mice 
Ten-week HFD+E treatment markedly induced liver injury in WT mice, as 
reflected by significantly increased serum levels of AST and ALT. Ten-week HFD plus 
acute alcohol did not alter the serum AST levels, but did increase ALT levels in Camp-/- 
mice. Depletion of CRAMP markedly reduced HFD+E induced liver injury as shown by 
decreased levels of serum ALT and AST (Figure 3.4A & B). Liver/body weight ratio 
dramatically increased under HFD+E conditions in WT mice, whereas no significant 
differences between HFD+E and CD+E were observed in Camp-/- mice. Lack of CRAMP 
significantly decreased liver/body ratio in HFD+E fed group (Figure 3.4C). Histological 
analysis revealed dramatically increased liver macrosteatosis in WT mice by HFD+E, 
while only mild microsteatosis was found in the livers of Camp-/- mice (Figure 3.4D). 
Confirming these results, significantly increased levels of liver triglyceride, free fatty 
acid and total cholesterol in WT mice by HFD+E were found, which were attenuated in 
Camp-/- mice (Figure 3.4E &F). Collectively, CRAMP deficiency decreased HFD+E 









Serum level of liver transaminases AST (A) & ALT (B). (C) Liver to body weight ratio. 
(D) H&E staining of paraffin-embedded liver tissue. Magnification: 100X. (E) Liver 
triglycerides contents. (F) Hepatic free fatty acids and cholesterol levels. Data are 
expressed as mean ± SEM, (n≥5). *p<0.05, **p<0.01, ***p<0.001.  
 
3.4.4 High Fat Feeding Increased Hepatic CRAMP Protein Level While Decreased 
CRAMP Protein Level in the Spleen 
Hepatic CRAMP expression induced by acute ethanol in HFD-fed WT mice were 
examined. Hepatic Camp mRNA was not affected by HFD+E (Figure 3.5A), but the 
protein levels of CRAMP significantly increased in the liver (Figure 3.5B). Two known 
transcription factors for Camp expression, vitamin D receptor (Vdr) and hypoxia 
inducible factor-1α (Hif-1α) were analyzed. HFD+E increased the expression of Vdr 
mRNA in WT mice 20 folds compared to the CD+E fed group, and this induction was not 
observed in Camp-/- mice. No changes were found in hepatic Hif-1α either by HFD+E 
feeding or CRAMP depletion (Figure 3.5C). P2x7 and Fpr2, genes encoding two 
documented receptors for cathelicidin LL-37/CRAMP, were not affected by HFD+E 
feeding in WT mice (Figure 3.5D). LL-37 has been reported to act as a functional ligand 
for the chemokine receptor CXCR2 on human neutrophils 158. Acute ethanol significantly 
up-regulated Cxcr-2 in HFD-primed liver in WT but not Camp-/- mice (Figure 3.5E). 
Importantly, Camp-/- mice fed with HFD+E had significantly reduced Cxcr-2 mRNA 
expression. Additionally, HFD+E treatment induced an induction of another chemokine 
receptor vascular cell adhesion molecule 1 (Vcam-1) in WT mice, but not in Camp-/- mice 
(Figure 3.5E), and Camp-/- mice had significantly reduced Vcam-1 mRNA by HDF+E 
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treatment. Immunofluorescence staining of liver tissue from WT mice fed CD+E or 
HFD+E revealed a colocalization of CRAMP and Ly6G-positive neutrophils, which were 
both increased by HFD+E feeding (Figure 3.5F). These results indicated that there is an 
enhanced neutrophil infiltration and chemokine expression by acute ethanol in HFD-
primed liver, which is possibly CRAMP-dependent. Previously it was showed that 
CRAMP is expressed predominantly in mouse spleen under physiological conditions, 
thus the expression of CRAMP in the spleen in the HFD+E model was evaluated. 
Surprisingly, Camp mRNA expression was not changed (Figure 3.5G), but CRAMP 
protein was significantly reduced in the spleens of WT mice following 10 weeks of HFD 
plus acute alcohol (Figure 3.5H). Additionally, spleen Vdr (Figure 3.5I) increased 
dramatically, while the mRNA expression of chemokine receptor CXCR-2 decreased 
significantly in WT mice (Figure 3.5J), indicting a possible organ-organ interaction in 







Figure 3.5 High fat feeding increased hepatic CRAMP protein level while decreased 
CRAMP protein level in the spleen.  
(A) Hepatic Camp expression. (B) Immunoblotting (left panel) and quantification (right 
panel) for CRAMP protein in mouse liver whole lysates. (C) Hepatic Vdr and Hif-1α 
mRNA expression. (D) Hepatic P2x7 and Fpr2 mRNA expression. (E) Hepatic Cxcr-2 
and Vcam-1 mRNA expression. (F) Immunofluorescence (IF) co-staining of Ly6G 
(Green) and Cathelicidin (Red) antibodies. Blue: DAPI for nucleus staining. (G) Spleen 
Camp expression. (H) Immunoblotting (left panel) and quantification (right panel) for 
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CRAMP protein in mouse spleen whole lysates. Spleen Vdr (I) and Cxcr-2 (J) mRNA 
expression. Data are expressed as mean ± SEM (n≥5). *p<0.05 
 
3.4.5 HFD Increased Inflammatory Monocytes and Neutrophils in the Liver of WT Mice 
HFD+E treatment induced an upregulation of CRAMP in the livers of WT mice, 
and this is accompanied by increased mRNA expression of two chemokine receptors. 
Whether HFD itself could induce infiltration of inflammatory cells in the liver was not 
explored. Hepatic leukocytes and spleen lymphocytes were isolated and stained as 
described in materials and methods, fixed and analyzed by flow cytometry. Immature 
myeloid cells play a crucial role in mediating inflammatory hepatic steatosis in a HFD 
mouse model and in ob/ob mice 173. The results showed that HFD feeding induced a 3-
fold increase in the percentage of CD11b+Gr-1+ immature myeloid cells in the liver 
compared to CD feeding in WT mice. Another 2-fold increased subpopulation in the 
CD11b+ cells with an intermediate intensity stained Gr-1 (CD11b+Gr-1int) was also 
detected in the livers of WT mice fed HFD (Figure 3.6A).  
Gr-1 is comprised of two components: Ly6C and Ly6G. Ly6G is exclusively 
expressed on neutrophils. Ly6C is expressed on a variety of cells but is most commonly 
used to distinguish monocyte subtypes. The inflammatory monocyte subset is Ly6C(hi), 
neutrophils and eosinophils are Ly6C(int), and the 'patrolling' monocyte subset is 
Ly6C(lo). Therefore, CD11b+Gr-1+ cells include monocytes, neutrophils, and eosinophils, 
while CD11b+Gr-1- cells represent Ly6C(lo) monocytes. The CD11b+ population was 
then further characterized by gating cells with anti-Gr-1 and anti-Ly6C antibodies. Two 
major subtypes were identified, CD11b+Gr-1+ Ly6C(int) neutrophils and CD11b+Gr-1+ 
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Ly6C(hi) inflammatory monocytes. HFD induced a significant increase in the populations 
of both neutrophils and inflammatory monocytes in the liver and the spleen. (Figure 
3.6B). Collectively, HFD induced the accumulation of immature myeloid cells in the 
livers of WT mice. Upon further characterization of the CD11b+Gr-1+ subpopulation, is 
was demonstrated that infiltrated CD11b+Gr-1+ Ly6C(int) neutrophils and CD11b+Gr-1+ 
Ly6C(hi) inflammatory monocytes were increased by HFD in the liver and spleen of WT 
mice.  
 
Figure 3.6 HFD feeding increased inflammatory monocytes and neutrophils in the 
livers of WT mice.  
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(A) Flow cytometry analysis of CD11b and Gr-1 positive leukocytes in the liver. Cell 
population labeled CD11b+Gr-1+ indicating immature myeloid; CD11b+Gr-1int indicating 
another subpopulation. (B) Flow cytometry analysis of gated CD11b and Gr-1 positive 
liver leukocytes by antibodies Ly6C. CD11b+Gr-1+ Ly6C(int) neutrophils and CD11b+Gr-
1+ Ly6C(hi) inflammatory monocytes were shown. 
 
3.4.6 HFD+E Treatment Enhances Neutrophil Clustering and Chemokine Expression in 
the Livers of WT Mice but not in Camp-/- Mice 
Next, we examined if the increased neutrophil infiltration in the livers of mice fed 
HFD+E is CRAMP-dependent. CAE staining showed a robust reduction of neutrophil 
infiltration in Camp-/- mice fed with HFD+E compared to their WT controls (Figure 
3.7A). Interestingly, the infiltrated neutrophils in the livers of CD+E fed WT mice 
scattered whereas neutrophils formed clusters in the livers of HFD+E fed WT mice 
(differentiated by black arrows and yellow arrow, respectively). However, this clustering 
of neutrophils was almost not detected in HFD+E fed Camp-/- mice (Figure 3.7A). 
Additionally, the number of neutrophil clusters and the area of formed clusters were 
significantly less and smaller in Camp-/- mice compared to WT mice (Figure 3.7B). This 
indicated that CRAMP may play a role in the recruitment and cluster formation of 
neutrophils under a HFD+E challenge. In addition, hepatic mRNA expression of Ly6G 
and chemokines, Mcp-1 and Cxcl-2, was significantly increased in the livers of HFD+E 
fed WT mice, which was reduced by the depletion of Camp gene (Figure 3.7C). This 
indicated that the depletion of CRAMP also reduces other chemokines that may 
contribute to HFD+E-induced neutrophil infiltration in mice. It was showed previously 
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that feeding Camp-/- mice with HFD+E significantly reduced the mRNA expression level 
of the chemokine receptor, CXCR-2, and that CRAMP may function as a CXCR-2 ligand 
in neutrophil chemotaxis. CXCL-1 is another well-defined CXCR-2 ligand, and we then 
evaluated whether the deletion of CRAMP affects the expression of CXCL-1 in HFD+E 
model. In WT mice, both acute ethanol and HFD feeding alone significantly increased the 
serum CXCL-1 concentration, and HFD+E treatment enhanced the induction of serum 
CXCL-1 compared to HFD feeding alone. However, this induction was not observed in 
Camp-/- mice (Figure 3.7D). HFD+E induces a two-fold increase in CXCL-1 levels 
compared to HFD feeding alone in WT mice but not in Camp-/- mice (Figure 3.7E). These 
data suggested that CRAMP acts as a chemoattractant for neutrophil infiltration induced 




Figure 3.7 HFD+E treatment enhanced neutrophil clustering and chemokine 
expression in the livers of WT mice but not in Camp-/- mice.  
(A) CAE staining of paraffin embedded liver tissue. Infiltrated scattered neutrophils: 
black arrows; clustered neutrophils: yellow arrow. (B) Quantified number of neutrophil 
96 
 
clusters (upper panel) and the area of formed clusters (lower panel) in the livers of 
HFD+E fed WT and Camp-/- mice. (C) Hepatic mRNA levels of Ly6G, Cxcr2-2 and Mcp-
1. (D) Serum CXCL-1 concentration analyzed by ELISA. (E) Fold change of serum 
CXCL-1 comparing CD+E vs CD and HFD+E vs HFD in WT and Camp-/- mice.  
 
3.5 Discussion  
Alcohol and obesity work synergistically in initiating and promoting alcohol 
associated liver disease (ALD) development. Obese alcoholics often have higher serum 
ALT levels and are more susceptible to progression from fatty liver to more advanced 
stages of ALD 36-43. Oxidative stress and nitrosative damage were linked to the 
synergistic effects of obesity and alcohol consumption in rodents. Studies using 
genetically obese rats and mice associated exacerbated hepatic steatosis and injury with 
increased pro-inflammatory response and the impairment of hepatic lipid metabolism. A 
recent study by Chang et al. showed that feeding mice with short- or long-term HFD plus 
a single ethanol binge synergistically increased the serum and hepatic free fatty acids, 
chemokine CXCL-1 expression, and exaggerated neutrophil infiltration in the liver, 
eventually progressing to severe liver injury 45. This suggests that exacerbated neutrophil 
infiltration may contribute to HFD+E-induced liver injury. 
In addition to anti-microbial potential 161-163, LL-37/CRAMP also has shown 
capacity to modulate inflammation and immunity 87,164-167. Zhang et al. demonstrated that 
LL-37 can act similarly to CXCR-2-specific chemokines CXCL1 in terms of receptor 
down-regulation and intracellular calcium mobilization on freshly isolated neutrophils. It 
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was hypothesized that the mouse cathelicidin, CRAMP, may play a role in HFD+E-
induced liver injury, by exerting its chemoattracting activity.  
10 weeks of HFD feeding significantly increased the body weight change in both 
WT and Camp-/- mice over time, while more profound weight gain was found in WT 
mice. HFD fed WT mice consumed much more food than HFD fed Camp-/- mice and had 
significantly higher body fat mass, reflected by the absolute weight of epidydimal white 
adipose tissue. Additionally, WT mice fed with HFD had dramatically enlarged 
adipocytes in the eWAT tissue compared to Camp-/- mice.  
Adipocytes play an important role in energy and glucose metabolism. In addition 
to serving as a site for energy storage (in the form of triglycerides), adipocytes act as 
endocrine cells, secreting molecules that regulate energy expenditure, food intake, and 
glucose metabolism. Recent findings suggest that the size of adipocytes is a major 
modulator of their endocrine function 176. In studies of bacteria-induced skin infection, 
researchers observed rapid proliferation of preadipocytes and expansion of the dermal fat 
layer after infection of the skin by Staphylococcus aureus. This host defense function was 
mediated through the production of CRAMP from adipocytes since CRAMP production 
was decreased by inhibition of adipogenesis, and adipocytes from Camp-/- mice lost the 
capacity to inhibit bacterial growth 177-179. This interesting study suggested a protective 
role of adipose tissue in inflammation-related systemic disease, and that the increased fat 
body mass by HFD treatment in WT mice in the present study could serve as a protective 
mechanism against HFD-induced pro-inflammatory response, which is associated with an 
up-regulation of CRAMP, from the inflammation aspect. In contrast to what was shown 
in the present study, i.e., that lacking CRAMP suppress the weight gain of mice fed with 
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HFD, another study demonstrated that Lentiviral cathelicidin overexpression reduced the 
fat mass of HFD-treated diabetic mice through inhibition of hepatic fatty acid translocase 
(CD36) 88. This implied a distinct function of exogenous and endogenous CRAMP in 
regulating lipid metabolism under different disease conditions.  
A significant difference in glucose tolerance between WT and Camp-/- mice was 
not observed by the end of 10 week-HFD feeding period. However, HFD feeding 
significantly increased the fasting serum glucose level and induced glucose intolerance in 
Camp-/- mice at an early stage but that was attenuated at a later stage; while HFD 
treatment increased fasting glucose levels and induced glucose intolerance over time in 
WT mice. It was further showed that Camp-/- mice were protected from HFD+E-induced 
liver injury and hepatic fat accumulation, suggesting that the deletion of CRAMP 
desensitized the mice to HFD-induced glucose intolerance and HFD+E-induced liver 
injury.  
Whether HFD+E treatment regulates CRAMP expression has not been reported 
yet. In the present study, the combination of HFD and alcohol consumption significantly 
increased CRAMP protein level in the liver, while the Camp mRNA was not changed by 
HFD+E. The induction of CRAMP was accompanied by significantly increased 
chemokine receptor CXCR-2, which plays a crucial role in neutrophil recruitment, 
suggesting that there is an enhanced neutrophil infiltration by HFD in the liver. Indeed, 
immunofluorescence staining of the neutrophil marker, Ly6G, revealed a much stronger 
positive staining in the livers of HFD+E fed WT mice compared to the CD+E fed 
controls, and interestingly, this was co-localized with increased hepatic CRAMP protein. 
Moreover, HFD+E treatment significantly decreased the protein level of CRAMP in the 
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spleens of WT mice, and surprisingly, spleen Cxcr-2 mRNA level was significantly 
reduced by HFD+E treatment. This implied a potential organ-organ interaction between 
the liver and the spleen regarding CRAMP regulation.  
Another interesting finding of this study is that CRAMP may involve in 
neutrophil clustering and thus, may enhance the pro-inflammatory response. HFD+E 
induced an increase of infiltrated neutrophils in both WT and Camp-/- mice, but they were 
more scattered in the livers of Camp-/- mice while being more clustered in WT mice. 
Camp-/- mice had significantly decreased hepatic mRNA levels of the chemokines Cxcl-2 
and Mcp-1, which were dramatically induced by HFD+E in WT mice.  
The clustering of neutrophils in the damaged sites is also referred to as neutrophil 
swarming 180, and a series of sequential phases have been described: (1) initial 
chemotaxis of individual neutrophils close to the damage; followed by (2) amplified 
chemotaxis of neutrophils from more distant interstitial regions; leading to (3) neutrophil 
clustering. In the third stage, swarming neutrophils can amplify their recruitment in a 
feed-forward manner through intercellular communication via leukotriene B4 (LTB4). 
The propagation of neutrophil recruitment leads to multiple, dense neutrophil cell clusters 
at the site of inflammation. Human cathelicidin LL-37 has been shown to induce LTB4 
by human macrophages 181 and LTB4, in turn, triggers the release of LL-37 from human 
neutrophils in innate immune responses 182. This suggests that CRAMP may play a role in 
regulating neutrophil clustering through macrophage-derived LTB4.  
Taken together, the studies in this chapter showed that Camp-/- mice were 
desensitized to HFD-induced body weight gain and adipocyte enlargement, and 
deficiency of CRAMP protected mice from HFD+E-induced liver injury and steatosis. 
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Importantly, HFD+E treatment induced a dramatic increase in neutrophil infiltration and 
chemokine expression in the livers of WT mice, which was not observed in Camp-/- mice. 
This indicated that CRAMP may act as a chemoattractant to enhance neutrophil 
infiltration induced by HFD+E treatment, causing exacerbated liver damage. In addition, 
significantly decreased mRNA levels of hepatic Tgf-β and Col-1a1 were found in Camp-/- 
mice compared to WT mice (data not shown), suggesting that CRAMP may play a role in 
hepatic stellate cells activation. More comprehensive and well-designed in vitro studies 
are needed to further confirm and elucidate the role of CRAMP in neutrophil regulation 




CHAPTER 4 SUMMARY AND DISCUSSION 
 
 
4.1 Cathelicidin (LL-37/CRAMP) and Its Role in Alcohol-associated Liver Disease 
Antimicrobial peptides (AMPs) are short and generally positively charged 
peptides found in a variety living organisms from bacteria to humans. AMPs were first 
identified and recognized as host defense peptides that can directly kill invading 
microorganisms. In addition to direct antimicrobial activity, AMPs carry 
immunomodulatory properties 183, which make them especially interesting compounds 
for the development of novel therapeutics. Several AMPs are currently being evaluated in 
clinical trials as novel anti-infectives, but also as new pharmacological agents to 
modulate the immune response, promote wound healing, and/or prevent post-surgical 
adhesions 170. The human gastrointestinal (GI) tract harbors a complex and dynamic 
population of microorganisms, the gut microbiota, which is now considered to be a 
hidden metabolic organ. Gut microbiota are crucially regulated by AMPs. The 
interdependence of the gut and the liver explains why disturbances in the intestinal 
barrier result in increased portal influx of bacteria or their products to the liver, where 
they cause or worsen a range of hepatic diseases/injury. The part played by intestinal 
microbes in liver diseases such as alcohol-associated liver disease (ALD) or bacterial 
infection in advanced liver disease has long been known 170. Previous studies have 
demonstrated critical role of AMPs in the pathogenesis of ALD 61,76,77. Reg3 lectins and 
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defensins were proved to be protective in ALD, through inhibition of pathogenic bacterial 
overgrowth and translocation of bacteria and toxic products into the liver 76,78. Moreover, 
overexpression of Reg3 lectin or synthetic human defensin attenuated alcohol-induced 
dysbiosis and liver injury.  
In the present dissertation, the role of another important AMP, cathelicidin 
(known as LL-37 in humans and CRAMP in mice) in alcohol-associated liver disease 
was investigated in two different experimental models using WT and Camp-/- mice. It 
was showed in Chapter 2 that CRAMP deficiency exacerbated ALD with enhanced 
inflammasome activation as shown by elevated serum IL-1β level. Although Camp-/- mice 
had comparable serum endotoxin levels compared to WT mice after alcohol feeding, 
hepatic LPS binding protein and CD14 were increased. Serum levels of UA, a signal 2 
molecule in inflammasome activation, were positively correlated with serum levels of IL-
1β in alcohol use disorder patients with ALD and were increased in Camp-/- mice fed 
alcohol. These data provided strong evidence regarding inflammasome regulation by 
CRAMP in ALD. It was furtherly showed in in vitro studies that CRAMP peptide 
inhibited LPS binding to macrophages and inflammasome activation stimulated by a 
combination of LPS and UA, and that deficiency of CRAMP induced increased 
production of UA possibly via enhanced oxidative stress. One of the most important 
experimental strategies of this study is the use of gain-of-function approach as a 
treatment by exogenously giving back synthetic CRAMP peptide to alcohol-fed WT and 
Camp-/- mice. CRAMP administration decreased serum UA and IL-1β concentrations and 
rescued the liver from alcohol-induced damage in both WT and Camp-/- mice.  
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Another mouse model of ALD was used in the study in Chapter 3. Long term 
HFD feeding plus binge alcohol gavage mimics acute ASH in obese binge drinkers and 
has great clinical implications. A recent study by Chang et al. showed that feeding mice 
with short- or long-term HFD plus a single ethanol binge synergistically increased the 
serum and hepatic free fatty acids, chemokine CXCL-1 expression and exaggerated 
neutrophil infiltration in the liver, eventually leading to severe liver injury 45. This 
suggests that exacerbated neutrophil infiltration may contribute to HFD plus alcohol-
induced liver injury. The finding that a single oral binge exposure of ethanol can trigger 
acute liver injury in the presence of short-term or long-term HFD feeding highlights the 
risk of even episodic binge drinking in obese/overweight individuals. LL-37/CRAMP 
were shown to act on freshly isolated neutrophils similarly to CXCR-2-specific 
chemokines (CXCL-1) in terms of receptor down-regulation and intracellular calcium 
mobilization 158. In Chapter 3, Camp-/- mice were desensitized to HFD-induced obesity 
and glucose intolerance; importantly, Camp-/- mice were protected against HFD+E-
induced liver injury, steatosis, neutrophil infiltration and pro-inflammatory chemokine 
expression. The study provided evidence that CRAMP functions in neutrophil trafficking 
regulation mainly through the well-characterized chemokine receptor CXCR-2, but not 
the other two receptors, FPR2 and P2X7, that have also been proposed as CRAMP 
receptors in macrophage regulation. This confirmed the notion that with HFD+E 
treatment, the immune regulatory activity of CRAMP leans more on the neutrophil 
chemoattracting aspect, but not on the TLR-4 mediated macrophage activation. 
Moreover, it was demonstrated in the present study that HFD+E induced increases in 
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infiltrated neutrophil number and cluster formation, and that Ly6G positive neutrophils 
colocalized with increased CRAMP protein in the livers of WT mice.  
CRAMP is expressed in multiple organs and different cell types, and the present 
study showed that CRAMP is highly expressed in the spleen under physiological 
conditions. Analyzing the CRAMP levels in the spleen revealed that HFD+E treatment 
significantly decreased the protein level of CRAMP in the spleen of WT mice, and 
surprisingly, spleen CXCR2 mRNA expression was significantly reduced by HFD+E. 
This implied a potential organ-organ interaction between the liver and the spleen for 
CRAMP regulation. The most interesting finding of this study is CRAMP may involve in 
neutrophil clustering and thus may enhance the pro-inflammatory response. HFD+E 
induced an increase of infiltrated neutrophils in both WT and Camp-/- mice, but they were 
more scattered in the livers of Camp-/- mice while being more clustered in livers of WT 
mice. Camp-/- mice also had significantly decreased hepatic mRNA levels of chemokines 
Cxcl-2 and Mcp-1, which were dramatically induced by HFD+E in WT mice. This 
indicated that the depletion of CRAMP also reduces other chemokines that may 
contribute to HFD+E-induced neutrophil infiltration in mice. 
A major question remains regarding the regulating activity of CRAMP in 
“inflammasome-inhibition” and “neutrophil-chemoattracting” in different disease models 
that were used in the present dissertation. CRAMP exacerbated binge alcohol-induced 
liver damage in chronic alcohol-primed mice, while attenuating binge alcohol-induced 
liver injury in HFD-primed mice. To try to answer this question, some of the key 
parameters in the two animal models were analyzed and compared side by side. HFD+E 
induced an increased F4/80 mRNA expression in the livers of WT mice, but not in Camp-
105 
 
/- mice, suggesting that HFD+E enhanced macrophage activation is suppressed by the 
deletion of CRAMP (Figure 4.1A). HFD+E treatment did not have an impact on 
inflammasome-dependent Il-1β and Il-18 mRNA expression in WT mice but significantly 
increased the anti-inflammatory cytokine Il-10 mRNA level. In contrast, HFD+E 
treatment significantly increased Il-1β and Il-18 mRNA expression with no change in Il-
10 mRNA expression in Camp-/- mice, indicating an increased level of inflammasome 
activation by HFD+E. This confirmed our observations in the 24D+1B alcohol feeding 
model that CRAMP deficiency exacerbated alcohol-induced Il-1β upregulation (Figure 
4.1B). However, this induction of Il-1β upregulation in Camp-/- mice may only have 
minimal effects on the overall inflammatory response in HFD+E treated mice, as HFD+E 
induces significantly higher levels of chemokines compared to binge on chronic ethanol 
feeding, according to two recent studies 45,184. From the LPS signaling aspect, HFD+E 
significantly induced serum endotoxin in WT but not Camp-/- mice, and HFD+E fed 
Camp-/- mice had much lower serum endotoxin levels compared to HFD+E fed WT mice 
(Figure 4.1C). Surprisingly, mRNA expression of Lbp was decreased by HFD+E 
treatment in WT mice while it was increased in Camp-/- mice. Camp-/- mice had 
significantly higher Lbp expression (Figure 4.1D). LBP has a concentration-dependent 
dual role in the pathogenesis of gram-negative sepsis: low concentrations of LBP enhance 
the LPS-induced activation of mononuclear cells (MNC), whereas the acute-phase rise in 
LBP concentrations inhibits LPS-induced cellular stimulation 185. This suggested that in 
Camp-/- mice, LPS-signaling might be inhibited by higher concentrations of LBP. Indeed, 
the mRNA expression of other two key molecules involved in LPS signaling, Cd14 and 
Tlr-4, were decreased in Camp-/- mice compared to WT mice fed with HFD+E (Figure 
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4.1D). The neutrophil infiltration in 24D+1B model in the livers of WT and Camp-/- mice 
were analyzed as well, with the addition of two synthetic CRAMP peptide treatment 
groups: AF+CRAMP WT and AF+CRAMP Camp-/-. Different from what was observed in 
the livers of WT mice fed HFD+E, no neutrophils clusters were detected in 24D+1B 
ethanol-fed WT mice. Importantly, exogenous CRAMP peptide increased neutrophil 
infiltration in the livers of 24D+1B ethanol-fed WT mice, which were decreased by 
CRAMP peptide treatment in the livers of AF fed Camp-/- mice (Figure 4.1E). This again, 
confirmed the chemoattracting role of CRAMP on neutrophils in WT mice, and indicated 
that exogenous CRAMP works differentially in terms of neutrophil infiltration under 








(A) Hepatic F4/80 mRNA. (B) Hepatic Il-1β, Il-18 and Il-10. (C) Serum endotoxin level. 
(D) Hepatic mRNA expression of Lbp, Cd14, Tlr-4. (E) CAE staining of liver tissue. 
Black arrow: infiltrated neutrophils. Data are expressed as mean ± SEM, (n≥5). *p<0.05, 
**p<0.01.  
 
4.2 Strengths and Weaknesses 
The studies in this dissertation explored the dual role of the antimicrobial peptide, 
CRAMP, in two different alcohol-associated liver disease models. The role of CRAMP is 
somewhat confounding, as it exhibits both pro-and anti-inflammatory activity. A major 
obstacle in the study of cathelicidins is the inability of exogenous LL-37 or CRAMP to 
mimic the activity of their endogenous counterparts. In Chapter 2, using a loss- and gain-
of function approach, we dissected the role of CRAMP in alcohol-induced liver injury in 
a 24 days chronic alcohol feeding plus one binge alcohol gavage model (24D+1B). 
CRAMP deficiency exacerbated, while exogenous CRAMP peptide alleviated, alcohol-
induced liver injury through inhibition of inflammasome activation by decreasing LPS 
function and uric acid (UA) production. The majority of the studies investigating the role 
of AMPs in ALD have been focused on the inhibition of pathogenic bacteria growth, and 
the inhibition of translocation of bacteria and toxic products from gut lumen to the liver. 
CRAMP deficiency induced gut microbiota dysbiosis, but more importantly, it was 
clearly demonstrated that CRAMP not only affects the gut microbiota homeostasis, but 
also participates in immune regulation. Camp-/- mice had increased levels of serum IL-1β, 
which is accompanied by the enhancement of LPS signaling and increased levels of uric 
acid production, both of which are critical signals required by NLRP3-dependent 
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inflammasome activation. Furthermore, the in vitro study showed that the deficiency of 
CRAMP induces UA production, possibly through exacerbated oxidative stress in the 
livers in ALD. Another strength of the study in Chapter 2 is the inclusion of human study. 
Analysis of the banked serum and liver biopsy samples from patients with ALD 
confirmed the observations in animal study and demonstrated that human cathelicidin, 
LL-37, is dysregulated in ALD and there is a positive correlation between serum IL-1β 
and serum UA concentrations.  
The animal model in Chapter 3 simulated acute alcohol-induced liver damage in 
obese binge drinkers. Camp-/- mice are protected from HFD+E-induced liver injury, and 
this is possibly due to the deficiency of CRAMP, which leads to reduced body weight 
gain and food intake. Importantly, the impairment of neutrophil infiltration under HFD+E 
stimulation. Camp-/- mice are also desensitized to HFD-induced glucose intolerance over 
time, suggesting other mechanisms exist in addition to the chemoattracting activity of 
CRAMP. It could not be ignored that CRAMP may directly affect lipid metabolism and 
gut barrier function, as the more pronounced enlargement of adipocytes were seen in WT 
mice but not in Camp-/- mice. WT mice also had increased levels of serum endotoxin, 
which were not seen in Camp-/- mice. 
Another concern is the unique expression pattern of CRAMP in different organs 
and cell types. It was shown in the 24D+1B model that CRAMP is highly expressed in 
the spleen and eWAT under physiological conditions, and CRAMP is upregulated by 
alcohol consumption at the mRNA and protein levels. However, it is not clear where this 
accumulated CRAMP protein in the liver comes from. In Chapter 3, IF staining revealed 
a colocalization of CRAMP and Ly6G-positive neutrophils in the livers of WT mice by 
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HFD+E treatment, but this is not exclusive. CRAMP acts as a chemoattractant to recruit 
neutrophils, however, the neutrophils themselves produce a lot of CRAMP upon 
stimulation. It is still an open question as to whether CRAMP is expressed mainly in the 
liver by hepatocytes or by the resident macrophages (Kupffer cells), by the infiltrated 
neutrophils, or whether CRAMP traveled as a hormone that was originally secreted by 
other organs, such as the spleen, upon alcohol exposure. 
Another weakness of this study is the limited sample size of human biopsies. The 
discrepancies of cathelicidin regulation in ALD patients and healthy controls could be 
attributed to the small sample size 186,187.   
In summary, the dual role of CRAMP in alcohol-associated liver disease have 
been explored in two experimental models of ALD. CRAMP plays a protective role in 
binge alcohol-induced liver injury in chronic alcohol-primed liver, through the inhibition 
of LPS and UA-induced inflammasome activation. However, CRAMP acts as a 
chemoattractant in HFD-primed liver to enhance the recruitment and aid in the trafficking 
and activation of neutrophils, which makes the liver prone to binge alcohol-induced liver 
damage as a second hit. The divergent effects of CRAMP in different ALD models 
revealed in this dissertation provide a better understanding of the complex roles of 
cathelicidin in alcohol-associated liver disease. With the presence of obesity as a 
comorbidity for the disease progression, the activity of cathelicidin is modulated by 
complex interactions with the microenvironment as well as with the disease background. 
The inhibitory effects on inflammasome activity and the enhancement on neutrophil 
infiltration in different disease models by CRAMP emphasized the importance of the 
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critical balance between anti- and pro-inflammatory responses upon tissue damage and 
that the role of CRAMP in alcoholic liver disease is dependent on the disease status.  
 
4.3 Future Directions 
4.3.1 Further Validation of the Inhibitory Effects of CRAMP on LPS Signaling and Uric 
Acid Production and Metabolism  
CRAMP deficiency exacerbated alcohol-induced live injury through inhibition of 
inflammasome priming and activation signals. Deletion of CRAMP led to increased LPS 
signaling protein and increased serum UA in alcohol fed mice, and serum UA levels were 
positively correlated with IL-1β concentrations in ALD patients. Although it was shown 
in an in vitro study that CRAMP, indeed, inhibits LPS binding to macrophages in a dose-
dependent manner, the in vivo evidence is still lacking. Immunoprecipitation assay could 
be done using serum and liver lysates samples from alcohol fed WT and Camp-/- mice, to 
examine the interactions of CRAMP between LPS and its signaling proteins in vivo. 
Additionally, the mechanisms through which CRAMP regulates UA production have not 
been completely addressed in this dissertation. The present study showed an increased 
ROS formation in the livers of Camp-/- mice, and that hepatocytes transfected with Camp-
targeting siRNA produced more UA in the supernatant than non-targeting siRNA-
transfected hepatocyte, indicating that CRAMP might regulate UA production by the 
hepatocytes through the induction of oxidative stress. But other cell types in the liver, 
such as Kupffer cells, also produce uric acid following alcohol treatment. The effects of 




4.3.2 Evaluation of Lipid Metabolism Regulation by CRAMP  
In 24D+1B model, synthetic CRAMP peptide treatment almost completely 
reversed hepatic fat accumulation in alcohol fed-WT and Camp-/- mice. In HFD+E 
feeding model, a drastic reduction of liver steatosis and adipocyte enlargement was 
observed in Camp-/- mice. While the present studies focused on the inflammasome 
activation and neutrophil infiltration, it is worth noting that CRAMP may have a direct 
impact on lipid metabolism in the liver and adipose tissue. Analysis on the fatty acid 
synthesis, oxidation and transportation could be conducted to elucidate the potential role 
of CRAMP on lipid metabolism in mice under physiological conditions and under binge 
alcohol challenged conditions in chronic ethanol or long term HFD-fed mice. 
 
4.3.3 Determine the Effects of CRAMP on Gut Barrier Function 
Binge on chronic alcohol-fed Camp-/- mice had comparable serum endotoxin 
levels compared to their WT controls, while binge alcohol in HFD-fed Camp-/- mice 
produced significantly lower levels of serum endotoxin than in WT mice. This implies a 
distinct regulation pattern of CRAMP on gut barrier function under different disease 
status. Tight junction proteins and permeability assays can be performed to examine the 
role of CRAMP in regulating gut barrier function in different ALD models. 
 
4.3.4 Further Evaluation of Neutrophil Infiltration Regulation by CRAMP through 
Chemokine Receptor CXCR-2  
Additional in vitro study is still needed to further confirm the hypothesis that 
CRAMP acts through the chemokine receptor, CXCR2, to recruit neutrophils in HFD+E 
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feeding model. Cxcr-2-/- mice could be used in the animal model applied in Chapter 3, to 
see whether HFD+E induces CRAMP expression in Cxcr-2-/- mice, and whether 
neutrophil infiltration is suppressed in Cxcr-2-/- mice due to the loss of receptor that 
CRAMP acts through. Another in vitro study could be designed using synthetic CRAMP 
peptide-treated neutrophils isolated from WT and Cxcr-2-/- mice, to determine if CRAMP 
peptide treatment increases neutrophil migration through the induction of CXCR-2 by the 
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Appendix 1 List of Abbreviations 
24D+1B 24 days of ethanol feeding plus 1 binge ethanol gavage 
AAH Acute alcoholic hepatitis  
ADH Alcohol dehydrogenase 
AF Alcohol fed 
ALD Alcoholic liver disease 
ALDH2 Aldehyde dehydrogenase 
ALT Alanine aminotransferase 
AMP Antimicrobial peptides 
ASC Apoptosis-associated speck protein with a caspase activation and 
recruitment domain 
ASH Alcohol-associated steatohepatitis 
AST Aspartate aminotransferase 
ATP Adenosine 5’-triphosphate 
AUD Alcohol use disorder 
BCA Bicinchoninic acid assay 
BHI Brain heart infusion 
BMDM Bone marrow-derived macrophages 
BSA Bovine serum albumin 
BW Body weight 
CAE Chloracetate esterase 
CD  Control diet 
CD14 Cluster of differentiation 14 
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CD73 Cluster of differentiation 73 
CRAMP Cathelicidin-related antimicrobial peptide 
CV Central vein 
CXCL Chemokine (C-X-C motif) ligand 
CYP2E1 Cytochrome P450 2E1 
DAMPs Danger-associated molecular patterns 
DFO Desferrioxamine 
DHE Dihydroethidium 
DMEM Dulbecco's modified Eagle's medium 
DNA Deoxyribonucleic acid 
DNAse Deoxyribonuclease 
DSS Dextran sulfate sodium 
E. coli Escherichia coli 
ELISA Enzyme-linked immunosorbent assay 
EtOH Ethanol 
eWAT Epididymal white adipose tissue 
FAEE Fatty acid ethyl esters 
FBS Fetal Bovine Serum 
FFA Free fatty acid 
FITC Fluorescein isothiocyanate 
FPR1/FPR2 Formyl peptide receptor-like 1 / 2 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
H&E Hematoxylin and eosin 
H2O2 Hydrogen peroxide 
HC Healthy controls 
HCC Hepatocellular carcinoma 
HFD Hight fat diet 
HIF1 Hypoxia inducible factor 1 




IBD Inflammatory bowel disease 




LAL Limulus amebocyte lysate 
LB Lysogeny broth 
LBP LPS binding protein 
LGG Lactobacillus rhamnosus GG 
LPS Lipopolysaccharide 
LSEC Liver sinusoidal endothelial cells 
LTDH Lifetime drinking history 
Ly6G Lymphocyte antigen 6 complex locus G6D 
M-CSF Macrophage colony-stimulating factor 
MELD Model for end-stage liver disease 
MEM Minimum essential media 
MNC Mononuclear cells 
mRNA Messenger ribonucleic acid 
MRS De Man, Rogosa and Sharpe agar 
NADH Nicotinamide adenine dinucleotide 
NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic steatohepatitis  
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NIAAA National Institute on Alcohol Abuse and Alcoholism 
NLRP3 NLR family pyrin domain containing 3 
NT Non-targeting 
OCT Optimal cutting temperature compound 
OGTT Oral glucose tolerance test 
OTU Operational Taxonomic Units 
P2X7 P2X purinoceptor 7 
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PAMPs Pathogen-associated molecular patterns 
PF Pair fed 
PT Portal tract 
qRT-PCR Quantitative real time polymerase chain reaction 
REG3B or REG3G Antimicrobial-regenerating islet-derived (REG)-3 lectins B or G 
RIPA Radioimmunoprecipitation assay 
RNAse Ribonuclease 
ROS Reactive oxygen species 
rRNA Ribosomal ribonucleic acid 
SCFA Short chain fatty acid 
SDS-PAGE Sodium dodecyl sulfate- Polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
TBST Tris-buffered saline/Tween 20 
TG Triglyceride 
TLFB Timeline follow back 
TLRs Toll-like receptors 
TM7 Candidatus bacteria 
TNF-α Tumor necrosis factor α 
TUNEL Terminal deoxynucleotidyl transferase biotin-dUTP nick end 
labeling 
UA Uric acid 
VCAM-1 Vascular cell adhesion molecule 1 
VDR Vitamin D receptor 
WT Wild type 
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